Electrical ablation devices

Description

BACKGROUND

Electrical ablation has been employed in medicine for the removal and treatment of a variety of abnormal tissues or growths, such as cancers or tumors. Electrical ablation may be used to treat benign prostatic hyperplasia (BPH), restricted gastric tissue, menorrhagia, and to remove adipose tissue. Other uses include removal of excess skin following bariatric surgery. Tumors in solid organs, such as the liver or lungs, may be treated or destroyed using electric direct current (DC) pulses. The abnormal tissue may be removed or treated with energy delivered by electrodes attached to therapy probes. The electrodes are positioned proximate or in contact with the diseased tissue and then energized by a variety of energy sources.

Menorrhagia is a medical condition that describes heavy and prolonged menstrual bleeding. While there are many potential causes for menorrhagia, the most common include hormone (estrogen and progesterone) imbalance, pelvic inflammatory disease, uterine fibroids, and infection. Current treatments for menorrhagia include iron supplements, prostaglandin inhibitors, oral contraceptives, and in severe cases—endometrial ablation and hysterectomy. Endometrial ablation involves introducing a conforming bipolar electrode into the uterine cavity, insufflation of the uterine cavity with CO₂(to check for cavity integrity), and then application of bipolar RF energy to the uterine wall for 90 seconds or more. An alternative to RF ablation is ultrasonic ablation.

Bariatric surgery remains a popular and successful option to assist morbidly obese patients. The procedure substantially reduces the patient's body mass index and resolves many associated comorbidities of obesity. One of the potential problems associated with bariatric surgery is the excess skin remaining after the patient has lost substantial weight. The effects of bariatric surgery occur so quickly and with such an impact that the body loses weight at a much faster rate than it can reduce the excess skin previously needed for the larger body. Many patients who are self-conscious of their appearance will consult with cosmetic surgeons following the bariatric procedure to investigate options for having the excess skin surgically removed.

While current methods and devices used in electrical ablation are effective, one drawback with conventional electrical ablation therapy is the resulting permanent damage that may occur to the tissue. This may be particularly true with uterine tissue, where conventional ablation therapy could cause permanent damage and potentially may result in complications with becoming pregnant. Other drawbacks of conventional ablation therapy are cost, lengthy recovery periods, and it can be extraordinarily painful.

Accordingly, there remains a need for improved electrical ablation methods and devices. There is also a need to provide improved electrical ablation therapies over time.

FIGURES

The novel features of the various embodiments are set forth with particularity in the appended claims. The various embodiments, however, both as to organization and methods of operation, together with the advantages thereof, may be understood by reference to the following description taken in conjunction with the accompanying drawings as follows.

FIG. 1 illustrates one embodiment of an electrical ablation device shown in use.

FIG. 2 is a partial cross-sectional view of a wall of a hollow body lumen comprising the proximal end of the electrical ablation device in FIG. 1 attached therethrough.

FIG. 3 illustrates one embodiment of a connector configured for attachment through the wall of a hollow body lumen.

FIG. 4 is a cross-sectional view of one embodiment of the electrical ablation device in FIG. 1 shown in use in treatment of abnormal tissues or growths, such as cancers or tumors, formed in solid organs.

FIG. 5 is a cross-sectional view of one embodiment of an electrical ablation device shown in use in treatment of abnormal tissues or growths, such as cancers or tumors, formed in solid organs.

FIG. 6 illustrates one embodiment of an electrical ablation device shown in use.

FIG. 7A is a side view of one embodiment of the electrical ablation device in FIG. 6 attached to the liver.

FIG. 7B is a side view of the electrical ablation device in FIG. 6 with first and second plate electrodes slidably moved toward each other along the outer surface of a center post to compress the liver and concentrate the energy delivered to the tumor.

FIG. 7C is a cross-sectional view of one embodiment of the electrical ablation device in FIGS. 7A and 7B.

FIG. 8A illustrates one embodiment of an electrical ablation device being deployed through a tumor in the liver.

FIG. 8B illustrates one embodiment of the electrical ablation device in FIG. 8A with a first arm electrode deployed.

FIG. 8C illustrates one embodiment of the electrical ablation device in FIG. 8A with first and second arm electrodes deployed.

FIG. 8D illustrates the liver slightly compressed by the first and second arm electrodes of the electrical ablation device in FIG. 8A.

FIG. 9 is a side view of one embodiment of the electrical ablation device in FIG. 8A.

FIG. 10 illustrates a spring-loaded arm portion of one embodiment of the electrical ablation device in FIG. 9.

FIG. 11A illustrates one embodiment of an electrical ablation device being deployed through a tumor and a liver.

FIG. 11B illustrates first and second electrodes of one embodiment of the electrical ablation device in FIG. 11A slidably opened.

FIG. 11C illustrates a liver slightly compressed by the first and second electrodes of the electrical ablation device in FIG. 11A.

FIG. 11D is a top-view of one embodiment of the first electrode of the electrical ablation device in FIG. 11A shown in an open position.

FIG. 12 illustrates one embodiment of an electrical ablation device attached to a solid organ prior to being connected to an energy source.

FIG. 13 illustrates one embodiment of an electrical ablation device.

FIG. 14A illustrates a balloon electrode of the electrical ablation device shown in FIG. 13 in a deflated state inserted into the cervix.

FIG. 14B illustrates the balloon electrode shown in FIG. 14A inserted in the uterine cavity in a partially inflated state.

FIG. 15A illustrates one embodiment of an electrical ablation device shown in use entering the cervix with the balloon electrode in a deflated state.

FIG. 15B illustrates one embodiment of the balloon electrode inserted through the cervix and into the uterine cavity in an inflated state.

FIG. 16 illustrates one embodiment of an electrical ablation device for removing excess skin.

FIG. 17 illustrates one embodiment of an electrical ablation device for removing excess skin.

FIG. 18 is a detail cross-sectional view of one embodiment of one embodiment of the electrode shown in FIG. 17.

FIG. 19 illustrates one embodiment of an electrical ablation device shown in use percutaneously, through the patient's skin.

FIG. 20 illustrates one embodiment of a wireless electrical ablation device shown in use.

DESCRIPTION

Various embodiments are described to provide an overall understanding of the structure, function, manufacture, and use of the devices and methods disclosed herein. One or more examples of these embodiments are illustrated in the accompanying drawings. Those of ordinary skill in the art will understand that the devices and methods specifically described herein and illustrated in the accompanying drawings are non-limiting embodiments and that the scope of the various embodiments is defined solely by the claims. The features illustrated or described in connection with one embodiment may be combined, in whole or in part, with the features of other embodiments. Such modifications and variations are intended to be included within the scope of the claims.

It will be appreciated that the terms “proximal” and “distal” are used herein with reference to a clinician manipulating one end of an instrument that protrudes out of a natural orifice (or opening) of the patient. The term “proximal” refers to the portion of the instrument closest to the clinician and the term “distal” refers to the portion located furthest from the clinician. It will be further appreciated that for conciseness and clarity, spatial terms such as “vertical,” “horizontal,” “up,” and “down” may be used herein with respect to the drawings. However, surgical instruments may be used in many orientations and positions, and these terms are not intended to be limiting and absolute.

The electrical ablation devices comprise electrodes that can be positioned inside a patient proximal to a treatment region (e.g., target site or worksite) where there is evidence of abnormal tissue growth. The electrodes comprise an electrically conductive portion (e.g., medical grade stainless steel) and are coupled to an energy source. Once the electrodes are positioned proximal to the treatment region, an energizing potential is applied to the electrodes to deliver electric current to the treatment region to remove the abnormal tissue. The electric current is supplied by an external energy source having a control unit or generator. The energizing potential (and the resulting electric current) may be characterized by a particular waveform in terms of frequency, amplitude, pulse width, and polarity. Depending on the diagnostic or therapeutic treatment to be rendered, the electrode may be configured as either an anode (−) or a cathode (−) or may comprise a plurality of electrodes with at least one configured as an anode (+) and the at least one another one configured as the cathode (−). Regardless of the initial configuration, the polarity of the electrodes may be reversed by reversing the polarity of the output of the energy source.

The energy source generates an electric field having a suitable characteristic waveform output in terms of frequency, amplitude, pulse width, and polarity. Depending on the diagnostic or therapeutic treatment to be rendered, the therapy probes may comprise one electrode containing both a cathode and an anode or may contain a plurality of electrodes with at least one serving as a cathode and at least one serving as an anode. The electrodes may be energized with DC voltages and conduct currents at various frequencies, amplitudes, pulse widths, and polarities. The electrodes also may be energized with time-varying voltages and currents at amplitudes and frequencies suitable for rendering the desired therapy. A suitable energy source may comprise an electrical waveform generator adapted to deliver DC and/or time-varying energizing potentials characterized by frequency, amplitude, pulse width, and/or polarity to the electrodes. The electric current flows between the electrodes and through the diseased tissue proportionally to the potential (e.g., voltage) applied to the electrodes. In one embodiment, the energy source may comprise a wireless transmitter to deliver energy to the electrodes via one or more antennas.

The various embodiments of the electrical ablation devices described hereinbelow utilize electroporation or electropermeabilization techniques to apply external electric fields (electric potentials) to cell membranes to significantly increase the electrical conductivity and permeability of the plasma in the cell membranes. Irreversible electroporation (IRE) is the process of killing cells by applying large destabilizing electrical potentials across the cell membranes for a long period of time. IRE provides an effective method for destroying cells while avoiding some of the negative complications of heat-inducing therapies. Namely, IRE destroys cells without the use of heat and does not destroy cellular support structure or regional vasculature. Large destabilizing IRE electric potentials may be in the range of about several hundred to about several thousand volts applied across biological membranes over a distance of about several millimeters, for example, for a relatively long period of time. The destabilizing electric potential forms pores in the cell membrane when the potential across the cell membrane exceeds its dielectric strength causing the cell to die by processes known as apoptosis and/or necrosis. Embodiments of the electrical therapy devices may be employed in the treatment of cancer by destroying live abnormal (e.g., cancerous) tissue in-vivo through the delivery of destabilizing electric potential energy to diseased tissue to quickly create cell necrosis and ablation in the cells of tumors, masses, lesions, and other abnormal growths.

FIG. 1 illustrates one embodiment of an electrical ablation device 100 shown in use. In one embodiment, the electrical ablation device 100 may be used in treatment of abnormal tissues or growths, such as cancers or tumors, formed in or on solid organs, BPH, and restricted gastric tissue using IRE energy. In other embodiments, electrical ablation treatment may be applied using other forms of electrical energy, such as those described herein. In the illustrated embodiment, the electrical ablation device 100 is shown disposed between a hollow body lumen and a solid organ. In one embodiment, the electrical ablation device 100 comprises a proximal end 102 configured for attachment through the wall of a hollow body lumen and a distal end 103 configured for attachment to abnormal tissues or growths, such as cancers or tumors, formed in a solid organ. The proximal end 102 may be attached to tissue that is endoscopically, laparoscopically, percutaneously, or transcutaneously accessible. In one embodiment, the proximal end 102 may be attached through a hollow body lumen that is endoscopically, laparoscopically, percutaneously, or transcutaneously accessible. Examples of a hollow body lumen include, for example, the esophagus, the stomach, the intestines, the colon, and may include the peritoneal cavity. In one embodiment, the proximal end 102 may be attached through the body percutaneously or transcutaneously—through the patient's skin—such that the proximal end 102 may be coupled to the energy source 119 externally and the electrical ablation device 100 may be energized from outside the patient's body. In the embodiment illustrated in FIG. 1, the electrical ablation device 100 is disposed between the stomach 108 and the liver 112. The proximal end 102 is disposed through the stomach 108 and the distal end 103 is disposed through a tumor 110 formed in the liver 112. An electrode 104 at the distal end 103 is positioned through the liver 112 and the tumor 110. The proximal end 102 of the electrical ablation device 100 may be attached to the wall 118 (FIG. 2) of the stomach 108 and the distal end 103 of the electrical ablation device 100 may be attached to the liver 112.

FIG. 2 is a partial cross-sectional view of a wall 118 of a hollow body lumen comprising the proximal end 102 of the electrical ablation device 100 attached therethrough. In the embodiment illustrated in FIG. 2, the proximal end 102 of the electrical ablation device 100 is attached through the wall 118 of the stomach 108. Referring to FIGS. 1 and 2, the proximal end 102 of the electrical ablation device 100 comprises a connector 114 and a fastener 116, which is inserted through the wall 118 of the stomach 108 and is secured thereto. In one embodiment, the connector 114 and the fastener 116 may be inserted through the body percutaneously or transcutaneously. For example, the connector 114 and the fastener 116 may be inserted through the abdominal wall and may be secured thereto. The connector 114 may be formed as a semi-permanent port. The fastener 116 comprises first and second flanges 122a, 122b connected by a hollow shaft 130 defining a longitudinal opening. The flanges 122a, b provide for the transmural attachment of the connector 114 through the wall 118 of the stomach 108 and seal the opening through the wall 118 of the stomach 108 where the shaft 130 is received. A first cable 106 is received through the longitudinal opening in the shaft 130. The cable 106 may comprise one or more electrically conductive wires electrically coupled to the connector 114 to provide electrical communication through the wall 118 of the stomach 108. In the embodiment illustrated in FIG. 1, the connector 114 is coupled to a corresponding mating female plug 115 located inside the stomach 108. The plug 115 is coupled to an energy source 119 via a second cable 117, which also may comprise one or more electrically conductive wires. The cable 117 may be introduced into the stomach 108 through the access channel or working channel of a flexible endoscope, an overtube, or though a small—keyhole—incision in the abdomen.

FIG. 19 illustrates one embodiment of the electrical ablation device 100 shown in use percutaneously, through the patient's skin. In one embodiment, the connector 114 and the fastener 116 are inserted through the body percutaneously or transcutaneously. As illustrated in FIG. 19, for example, the connector 114 and the fastener 116 are be inserted through the abdominal wall 109 and may be secured thereto with the first and second flanges 122a, 122b connected by the hollow shaft 130. The flanges 122a, b provide for the transmural attachment of the connector 114 through the abdominal wall 109 and seal the opening where the shaft 130 is received. The plug 115 is coupled to the connector 114 one end and to the energy source 119 on another end by the second cable 117, which also may comprise one or more electrically conductive wires.

Referring back to FIGS. 1 and 2, in one embodiment, the connector 114 may be attached to the wall 118 of the stomach 108 using a variety of fasteners. The connector 114 opens to the inside of the stomach 108 and the fastener 116 is used to attach the connector 114 to the wall 118 of the stomach 108. The energy source 119 is coupled to the connector 114 via the plug 115. Electrical energy generated by the energy source 119 are communicated by the cable 117 and the connector 114 through the wall 118 of the stomach 108. The electrical energy is communicated by the cable 106 to the electrode 104. As described in more detail with reference to FIG. 20, in one embodiment the electrical energy is communicated to the electrode 104 wirelessly by way of one or more antennas.

Referring to FIG. 1, in one embodiment, the electrode 104 may be attached to the tumor 110 and/or the liver 112 using a variety of fasteners. The electrode 104 is located approximately in the center of the tumor 110. In one embodiment, the electrode 104 may be configured as an anode (+) coupled to a positive terminal of the energy source 119. A second electrode may be configured as a cathode (−) coupled to a negative terminal of the energy source 119 to form a conductive return path or surface and may be located in the stomach 108 or elsewhere. It will be appreciated that the electrode 104 may be configured either as the anode (+) or the cathode (−) and the polarity of the electrode 104 may be reversed by reversing the output of the energy source 119. In one embodiment, the second electrode may be an electrically conductive balloon (not shown) located in the stomach 108 or other internal body lumen. The first and second electrodes may be inserted inside the patient's body using laparoscopic or endoscopic minimally invasive surgical techniques.

FIG. 3 illustrates one embodiment of the connector 114 configured for attachment through the wall 118 of a hollow body lumen. In the embodiment illustrated in FIG. 3, the connector 114 comprises a body 120 and the flange 122a. In one embodiment, the first flange 122a comprises one or more openings 124 for receiving sutures or tags for attaching the connector 114 to the wall 118 of the stomach 108 (both shown in FIG. 2). Although not shown in FIG. 3, the second flange 122b may comprise similar openings for receiving sutures or tags for attaching the connector 114 to the wall 118 of the stomach 108. The connector 114 comprises one or more terminals 128a, 128b, for example, to receive a corresponding female plug (e.g., plug 115 shown in FIG. 1) configured to connect to the first and second terminals 128a, 128b. First ends of the one or more electrically conductive wires disposed in the cable 106 are connected to the one or more terminals 128a, b. The body 120 also includes a first and second recesses 126a, 126b (126b not shown) for receiving corresponding tabs formed on a mating female plug portion configured to electrically coupled to the connector 114. The body is formed of an electrically insulative material such as medical grade polyester, for example, to electrically isolate the one or more terminals 128a, b from the wall 118 of the stomach 108.

FIG. 4 is a cross-sectional view of one embodiment of the electrical ablation device 100 shown in use in treatment of abnormal tissues or growths, such as cancers or tumors, formed in solid organs. In the embodiment illustrated in FIG. 4, the electrode 104 is embedded into the tumor 110 formed in the liver 112. The distal end 103 of the electrical ablation device 100 comprises a connector 134 adapted to couple to the cable 106. The electrode 104 is adapted to embed into the liver 112 and the tumor 110. The electrode 104 comprises a tapered body for easy insertion into solid body organs. In one embodiment, the electrode 104 may be formed in the shape of a needle electrode. Ridges 105 may be formed on an outer surface of the tapered body of the electrode 104 to allow for penetration attachment of the electrode 104 to tissue. The electrode 104 comprises at least one electrically conductive portion that is formed of or coated with an electrically conductive material such as medical grade stainless steel, for example.

FIG. 5 is a cross-sectional view of one embodiment of the electrical ablation device 100 shown in use in treatment of abnormal tissues or growths, such as cancers or tumors, formed in solid organs. In the embodiment illustrated in FIG. 5, an electrode 136 located at the distal end 103 of the electrical ablation device 100 is embedded into the tumor 110 formed in the liver 112. The distal end 103 of the electrical ablation device 100 comprises a connector 134 adapted to couple to the cable 106. The electrode 136 is adapted to embed into the liver 112 and the tumor 110. In the illustrated embodiment, the electrode 136 has a helical body (e.g., corkscrew) to penetrate and attach the electrode 136 into the liver 112 and the tumor 110. The electrode 136 comprises at least one electrically conductive portion formed of or coated with an electrically conductive material such as medical grade stainless steel, for example. In one embodiment, the electrode 136 may be configured as an anode (+) coupled to a positive terminal of the energy source 119. A second electrode may be configured as a cathode (−) coupled to a negative terminal of the energy source 119 to form a conductive return path or surface and may be located in the stomach 108 or elsewhere. It will be appreciated that the electrode 136 may be configured either as the anode (+) or the cathode (−) and the polarity of the electrode 136 may be reversed by reversing the output of the energy source 119. In one embodiment, the second electrode may be an electrically conductive balloon (not shown) located in the stomach 108 or other internal body lumen. The first and second electrodes may be inserted inside the patient's body using laparoscopic or endoscopic minimally invasive surgical techniques.

Referring to FIGS. 1-5, in one embodiment, the connector 114 and either one of the electrodes 104, 134 may be introduced into a hollow body lumen via a flexible endoscope using translumenal endoscopic access techniques. For convenience and brevity, the following process is described with reference only to the electrode 104 shown in FIGS. 1 and 4; however, those skilled in the art will appreciate that these techniques may be used in regards to the electrode 136 shown in FIG. 5 as well. A flexible endoscope is introduced into a natural body orifice such as the mouth, anus, or vagina. For example, the flexible endoscope may be introduced into the stomach 108 trans-orally. The cable 106 and the electrode 104 may be introduced into the stomach 108 through the working channel of the endoscope. An opening is formed through the wall 118 of the stomach 108 using translumenal access techniques, described in more detail below. The cable 106 and the electrode 104 are fed through the opening in the wall 118. The electrode 104 is inserted into the liver 112 and the tumor 110 and is secured or attached therein by the ridges 105 formed on the electrode 104. If the electrode 136 were being used, the helical body of the electrode 136 serves to penetrate and retain the electrode 136 in the liver 112 and the tumor 110. As shown in FIG. 2, the connector 114 is then attached to the wall 118 of the stomach 108 with sutures or tags inserted through the one or more openings 124 formed in the flanges 122a, b. Once the connector 114 is attached to the wall 118 of the stomach 108, the plug 115 and cable 117 may be inserted trans-orally through a working channel of the endoscope. The plug 115 is electrically coupled to the connector 114 inside the stomach 108. The plug 115 includes corresponding female receptors to receive the one or more terminals 128a, 128b and form an electrical connection. The first and second recesses 126a (FIG. 3), 126b (126b not shown) formed in the body 120 receive corresponding tabs formed on the mating female plug 115 portion to removably attach the plug 115 to the connector 114. The proximal end of the cable 117 is connected to the energy source 119 outside the patient's body. The electrical ablation therapy is then applied to the tumor 110.

Once the electrical ablation device 100 is positioned and the electrical connections are completed, the tumor 110 may be treated with electrical ablation energy supplied by the energy source 119. The electrical ablation energy may be delivered in many forms, as described in more detail below. Following the electrical ablation therapy, the plug 115 and the cable 117 are removed from the patient after disconnecting the plug 115 from the connector 114. If subsequent electrical ablation therapy is necessary to completely ablate the tumor 110, the plug 115 and the cable 117 are reinserted into the patient, the plug 115 is connected to the connector 114 and electrical ablation therapy is reinitiated. The tumor 110 may be monitored over time (e.g., days, weeks, or months) to observe shrinkage. The electrical ablation therapy may be repeated until the tumor 110 disappears. The electrical ablation device 100 remains inside the patient until the treatment of the tumor 110 is completed.

The electrical ablation device 100 is driven with electrical ablation energy supplied by the energy source 119 shown in FIG. 1. The input to the energy source 119 is connected to a commercial power supply by way of a plug (not shown). The output of the energy source 119 is coupled to the electrodes (e.g., electrode 104 or electrode 136) and energized with electrical ablation energy suitable to ablate abnormal (e.g., cancerous) tissues and destroy the tumor 110, for example. The energy source 119 may be configured to produce electrical ablation energy in various forms, as described in more detail below.

In one embodiment, the energy source 119 may be configured to produce pulsed or cyclical electrical ablation signals to electrically ablate abnormal tissue with the electrical ablation device 100. In one embodiment, a timing circuit may be used to interrupt the output of the energy source 119 and generate a pulsed output signal. The timing circuit may comprise one or more suitable switching elements to produce the pulsed output signal. For example, the energy source 119 may produce a series of n pulses (where n is any integer) suitable to treat the tumor 110 when the pulsed energy is applied to the electrodes (e.g., electrode 104 or electrode 136). The pulses may have a fixed or variable pulse width and may be delivered at any suitable frequency.

In one embodiment, the energy source 119 may be configured to produce electrical output waveforms at predetermined frequencies, amplitudes, polarities, and/or pulse widths to electrically ablate abnormal tissue with the electrical ablation device 100. When the electrical output waveforms are applied to the electrodes (e.g., electrode 104 or electrode 136), the resulting electric potentials cause currents to flow through the distal end of the electrodes to destroy abnormal tissue such as the tumor 110.

In one embodiment, the energy source 119 may be configured to produce radio frequency (RF) waveforms at predetermined frequencies, amplitudes, polarities, and pulse widths to electrically ablate abnormal tissue with the electrical ablation device 100. The energy source 119 may comprise a commercially available conventional, bipolar/monopolar electrosurgical RF generator such as Model Number ICC 350, available from Erbe, GmbH.

In one embodiment, the energy source 119 may be configured to produce irreversible electroporation (IRE) energy in the form of bipolar/monopolar pulsed DC output signals to electrically ablate abnormal tissue with the electrical ablation device 100. The energy source 119 may comprise a commercially available conventional, bipolar/monopolar Pulsed DC generator such as Model Number ECM 830, available from BTX Molecular Delivery Systems Boston, Mass. In bipolar mode a first electrode (e.g., electrode 104 or electrode 136) may be electrically coupled to a first polarity and a second electrode may be electrically coupled to a second (e.g., opposite) polarity. Bipolar/monopolar pulsed DC output signals (e.g., DC pulses) may be produced at a variety of frequencies, amplitudes, pulse widths, and polarities. For example, the energy source 119 may be configured to produce DC pulses at frequencies in the range of about 1 Hz to about 1000 Hz, amplitudes in the range of about ±100 to about ±3000 VDC, and pulse widths (e.g., pulse durations) in the range of about 1 μs to about 100 ms to electrically ablate the tumor 110. The polarity of the energy delivered to the electrodes (e.g., electrode 104 or electrode 136) may be reversed during the electrical ablation therapy. For example, the polarity of the DC pulses initially delivered at amplitudes in the range of about +100 to about +3000 VDC may be reversed to amplitudes of about −100 to about −3000 VDC. Preferably, the tumor 110 may be electrically ablated with DC pulses at frequencies of about 10 Hz to about 100 Hz, amplitudes in the range of about +700 to about +1500 VDC, and pulse widths of about 10 μs to about 50 μs. The IRE energy also may be used for the treatment of BPH and restricted gastric tissue.

In one embodiment, the energy source 119 may energize the electrode 104 through a wired or a wireless connection. In a wired connection, the energy source 119 is coupled to the electrode by way of one or more electrically conductive wires through the cable 106. As previously discussed, the cable 106 may connected to the connector 114, which may be inserted transmurally through a hollow body lumen, such as the wall 118 of the stomach 108, or percutaneously through the abdominal wall 109. In a wireless connection, the energy source 119 may be coupled to the electrode 104 by way of one or more antennas, thus eliminating the need to perforate the hollow body lumen or the patient's skin. In a wireless embodiment, the cable 106 may be replaced by an antenna 904 as shown in FIG. 19, for example. The antenna 904 is coupled to the electrode by an electrically conductive wire.

FIG. 6 illustrates one embodiment of an electrical ablation device 200 shown in use. In one embodiment, the electrical ablation device 200 may be used in treatment of abnormal tissues or growths, such as cancers or tumors, formed in or on solid organs, BPH, and restricted gastric tissue using IRE energy. In other embodiments, electrical ablation treatment may be applied using other forms of electrical energy, such as those described herein. In one embodiment, the electrical ablation device 200 comprises the connector 114 at the proximal end 102 and an electrode assembly 204 at the distal end 103. As previously discussed, the connector 114 is configured for attachment through the wall 118 of a hollow body lumen such as the stomach 108 to couple the electrical ablation device 200 to the energy source 119. The electrode assembly 204 is configured to attach to solid organ such as the liver 112 and electrically ablate abnormal tissues or growths such as the tumor 110 formed in the liver 112. As illustrated in FIG. 6, the connector 114 is attached to the wall 118 of the stomach 108 and the electrode assembly 204 is positioned on exterior surfaces of the liver 112 proximal to the tumor 110. The tumor 110 may be electrically ablated by the electrical ablation device 200 with electrical ablation energy supplied by the energy source 119.

The proximal end 102 of the electrical ablation device 200 is attached to the stomach 108 via the connector 114. As previously discussed, the connector 114 is attached to the wall 118 of the stomach 108 with sutures or tags inserted through the one or more openings 124 formed in the flanges 122a, b of the connector 114 as shown in FIG. 2. The connector 114 receives the corresponding mating female plug 115 inside the stomach 108 to electrically couple the energy source 119 to the electrical ablation device 200.

The distal end 103 of the electrical ablation device 200 is attached to the liver 112 via the electrode assembly 204. In one embodiment, the electrode assembly 204 comprises first and second plate electrodes 204a, 204b configured as electrodes and a center post 204c extending therebetween. The first and second plate electrodes 204a, b each comprise openings to receive the center post 204c. The center post 204c is inserted through the tumor 110 and through the openings formed in the first and second plate electrodes 204a, b. The first and second plate electrodes 204a, b are positioned opposite each other on outer surfaces of the liver 112. The first and second plate electrodes 204a, b are slidably movable along an outer surface of the center post 204c. Thus, the distance D (shown in FIGS. 7A and 7C) between the first and second plate electrodes 204a, b may be adjusted according to the size of the liver 112. In the illustrated embodiment, the first plate electrode 204a is located above the tumor 110 and the second plate electrode 204b is located below the tumor 110. Once positioned, the first and second plate electrodes 204a, b may be adjusted to slightly compress the liver 112. The first and second plate electrodes 204a, b each comprises at least one electrically conductive portion that is formed of or coated with an electrically conductive material such as medical grade stainless steel, for example, and are electrically coupled to respective first and second electrically conductive wires of the cable 106 to deliver electrical ablation energy to the tumor 110 from the energy source 119. The center post 204c is formed of an electrically insulative material such as medical grade polyester, for example, to electrically isolate the center post 204c from the first and second plate electrodes 204a, b. In one embodiment the first plate electrode 204a may be configured as the anode (+) electrode coupled to the positive terminal of the energy source 119 and the second plate electrode 204b may be configured as the cathode (−) electrode coupled to the negative terminal of the energy source 119. It will be appreciated that the polarity of the first and second plate electrodes 204a, b may be reversed such that the first plate electrode 204a is configured as the cathode (−) electrode and the second plate electrode 204b is configured as the anode (+) electrode by reversing the output polarity of the energy source 119.

In one embodiment, electrical ablation device 200 including the first and second plate electrodes 204a, b may be introduced to the treatment site (e.g., the tumor 110) endoscopically, laparoscopically, or through various translumenal access techniques. As previously discussed, a flexible endoscope may be introduced into the stomach 108 trans-orally and the cable 106 may be fed through the access or working channel of the endoscope. The cable 106 and the electrode 104 are initially placed in the stomach 108. The wall 118 of the stomach 108 is perforated using translumenal access techniques. The cable 106 and the electrode assembly 204 are advanced through the trans-mural opening and the electrode assembly 204 is attached to the liver 112. The plug 115 and the cable 117 are then inserted trans-orally through the working channel of the endoscope. The plug 115 at the distal end of the cable 117 is electrically coupled to the connector 114 inside the stomach 108. The proximal end of the cable 117 is connected to the energy source 119 outside the patient's body. The tumor 110 is then treated with electrical ablation energy supplied by the energy source 119. After the electrical ablation therapy is completed, the plug 115 may be removed from the connector 114 and the plug 115 and the cable 117 removed from inside the patient. The plug 115 and the cable 117 may be reinserted into the patient for subsequent electrical ablation therapy. The tumor 110 may be monitored over time (e.g., days, weeks, or months) to observe shrinkage. The electrical ablation therapy may be repeated until the tumor 110 disappears. The electrical ablation device 200 remains inside the patient until the tumor 110 is completely ablated. It will be appreciated that the electrode assembly 204 may be repositioned to treat tumors that are larger than the surface area of the first and second plate electrodes 204a, b. In various other embodiments, the first and second plate electrodes 204a, b of the electrical ablation device 200 may be coupled to the energy source 119 percutaneously through the abdominal wall 109 (FIG. 19) or wirelessly by replacing the cable 106 with the antenna 904 (FIG. 20). The antenna 904 is coupled to the first plate electrode 204a by a first electrically conductive wire and the antenna 904 is coupled to the second plate electrode 204b by a second electrically conductive wire.

FIGS. 7A and 7B are side views of one embodiment of the electrical ablation device 200 shown in use in treatment of a tumor formed in a solid organ using IRE energy. As shown in FIG. 7A, the electrical ablation device 200 is attached to the liver 112. The first and second plate electrodes 204a, b are placed above and below the tumor 110 on the outer surface of the liver 112. In FIG. 7B, the first and second plate electrodes 204a, b have been slidably moved toward each other along the outer surface of the center post 204c to compress the liver 112 to a distance D₁, which is less than the distance D shown in FIG. 7A. Compression of the liver 112 helps to concentrate the energy delivered to the tumor 110 as well as reduce the voltage required to ablate the tumor 110. Furthermore a more homogeneous electric field can be applied with using the parallel plates configuration of the first and second plate electrodes 204a, b. The first and second plate electrodes 204a, b are electrically coupled to the energy source 119 (FIG. 6) via the cable 106. The output of the energy source 119 is set to create a voltage difference between the first and second plate electrodes 204a, b that is high enough to produce an electric field, represented by iso-lines 210, sufficient to electrically ablate the tumor 110. The potential energy level of the electric field may be in the order of about 1e5 volts/meter. The potential energy level is sufficient to destroy the tumor 110 and the tissue surrounding the tumor 110.

FIG. 7C is a cross-sectional view of one embodiment of the electrical ablation device 200. The first and second plate electrodes 204a, b are separated by a distance D, which is adjustable by slidably moving the first and second plate electrodes 204a, b along an outer surface 214 of the center post 204c. First and second conductors 212a, 212b are electrically connected to the respective first and second plate electrodes 204a, b. The first and second conductors 212a, b are provided through respective openings 216a, 216b formed through the center post 204c. The first and second conductors 212a, b are contained in respective insulative sheathes 220a, b and are housed within an electrically insulative outer sheath 218 of the cable 106. In the illustrated embodiment, the first and second conductors 212a, b are coupled to the respective positive (+) and negative (−) terminals of the energy source 119 (FIG. 6) through the connector 114 (FIG. 6), for example. In other embodiments, the polarity of the first and second conductors 212a, b may be reversed. The first and second plate electrodes 204a, b may be locked into position against the center post 204c once adequate compression has been applied to the liver 112 as shown in FIG. 7B. In one embodiment, the first and second plate electrodes 204a, b are maintained at a desired distance D from each other by frictionally engaging the outer surface 214 of the center post 204c with the inner surfaces defined by the openings 222a, 222b. In other embodiments, various features may be provided on the outer surface 214 of the center post 204c and the inner surface defined by the openings 222a, 222b in the respective first and second plate electrodes 204a, b to lock the first and second plate electrodes 204a, b at a desired distance D from each other. These features may include corresponding male and female threaded surfaces, ratcheting surfaces, and grooves with detents, for example.

With reference to FIGS. 6 and 7A-C, the tumor 110 may be electrically ablated by applying IRE energy to the first and second plate electrodes 204a, b of the electrode assembly 204. As previously discussed, the energy source 119 DC pulses at frequencies in the range of about 1 Hz to about 1000 Hz, amplitudes in the range of about ±100 to about ±3000 VDC, and pulse widths (e.g., pulse durations) in the range of about 1 μs to about 100 ms to the first and second plate electrodes 204a, b of the electrode assembly 204. The polarity of the energy delivered to the electrodes (e.g., electrode 104 or electrode 136) may be reversed during the electrical ablation therapy. For example, the polarity of the DC pulses initially delivered at amplitudes in the range of about +100 to about +3000 VDC may be reversed to amplitudes of about −100 to about −3000 VDC. Preferably, the tumor 110 may be electrically ablated with DC pulses at frequencies of about 10 Hz to about 100 Hz, amplitudes in the range of about +700 to about +1500 VDC, and pulse widths of about 10 μs to about 50 μs.

FIGS. 8A-D are side views of one embodiment of an electrical ablation device 300 shown in various stages of deployment. In one embodiment, the electrical ablation device 300 may be used in treatment of abnormal tissues or growths, such as cancers or tumors, formed in or on solid organs, BPH, and restricted gastric tissue using IRE energy. The electrical ablation device 300 may be used to electrically ablate abnormal tissues or growths, such as cancers or tumors, formed in solid organs using IRE energy. In other embodiments, electrical ablation treatment may be applied using other forms of electrical energy, such as those described herein.

FIG. 8A illustrates one embodiment of the electrical ablation device 300 being deployed through the tumor 110 and the liver 112. In the illustrated embodiment, the electrical ablation device 300 comprises an electrode assembly 302 that is attachable to a solid organ such as the liver 112. In one embodiment, the electrode assembly 302 comprises a sharp distal end 304 suitable for penetrating the liver 112 and the tumor 110. The electrode assembly 302 comprises first and second arm electrodes 302a, 302b configured as first and second electrodes. The first and second arm electrodes 302a, b are initially folded and contained within a hollow body 308 of the electrode assembly 302 to enable the electrode to pierce and penetrate the liver 112 and the tumor 110 with the sharp distal end 304. The first and second arm electrodes 302a, b each comprises at least one electrically conductive portion that is formed of or coated with an electrically conductive material such as medical grade stainless steel, for example, and are coupled to the energy source 119 (previously described with reference to FIGS. 1-5) through one or more electrically conductive wires 220a, b that form the cable 106 as shown in FIG. 7C. The hollow body 308 is formed of an electrically insulative material such as medical grade polyester, for example, to electrically isolate the hollow body 308 from the first and second arm electrodes 302a, b. In one embodiment the first arm electrode 302a may be configured as the anode (+) electrode coupled to the positive terminal of the energy source 119 and the second arm electrode 302b may be configured as the cathode (−) electrode coupled to the negative terminal of the energy source 119. It will be appreciated that the polarity of the first and second arm electrodes 302a, b may be reversed such that the first arm electrode 302a is configured as the cathode (−) electrode and the second arm electrode 302b is configured as the anode (+) electrode by reversing the output polarity of the energy source 119.

As previously discussed, the cable 106 is attached to the connector 114 through the wall 118 of the stomach 108 using techniques previously described with reference to FIGS. 1-3 and 6, for example. The first and second arm electrodes 302a, b are pivotably movable about respective pivot points 310a, 310b. In various other embodiments, the first and second arm electrodes 302a, b of the electrical ablation device 300 may be coupled to the energy source 119 percutaneously through the abdominal wall 109 (FIG. 19) or wirelessly by replacing the cable 106 with the antenna 904 (FIG. 20). The antenna 904 is coupled to the first arm electrode 302a by a first electrically conductive wire and the antenna 904 is coupled to the second arm electrode 302b by a second electrically conductive wire.

FIG. 9 is a side view of one embodiment of the electrical ablation device 300. FIG. 10 illustrates a spring-loaded arm portion of the embodiment of the electrical ablation device 300 shown in FIG. 9. As shown in FIGS. 8B, 8C, 9, and 10, the first and second arm electrodes 302a, b are pivotally movable outwardly in the directions shown by arrows A and B through respective longitudinal slots 312a, 312b formed in the hollow body 308 of the electrode assembly 302. In one embodiment, the first and second arm electrodes 302a, b are spring loaded and may be actuated by internal springs or other actuation mechanisms. As shown in FIG. 10 the first arm electrode 302a comprises a spring 316 to open the first arm electrode 302a outwardly in direction A. Although not shown, the second arm electrode 302b also comprises a spring 316 to open the second arm electrode 302b outwardly in direction B.

Referring to FIGS. 8A-D, the illustrated embodiment of the electrical ablation device 300 is shown in use in treatment of the tumor 110 formed in the liver 112 using electrical energy. As shown in FIG. 8A, the first and second arm electrodes 302a, b are folded and spring loaded inside the hollow body 308 of the electrode assembly 302. The distal end 304 of the electrode assembly 302 is inserted in direction C into one side of the liver 112, through the tumor 110, and out the other side of the liver 112. As shown in FIG. 8B, the distal end 304 of the electrode assembly 302 is pushed in direction C through the other side of the liver 112 until the first arm electrode 302a is exposed in the hollow body lumen 314 surrounding the liver 112 enabling the first arm electrode 302a to spring open in direction A under the force of the spring 316 (FIG. 10). Once the first arm electrode 302a is deployed, the electrode assembly 302 is retracted by pulling in direction D until the second arm electrode 302b is exposed in the hollow body lumen 314 surrounding the liver 112 and enabling the second arm electrode 302b to open in direction B, as shown in FIG. 8C. As shown in FIG. 8D the liver 112 may be slightly compressed such that y₂<y₁, where y₁is the pre-compressed thickness of the liver 112 and y₂is the compressed thickness of the liver 112.

As shown in FIG. 8D, the tumor 110 may be electrically ablated by applying IRE energy to the electrode assembly 302 when the first and second arm electrodes 302a, b are deployed. As previously discussed, the energy source 119 (previously described with reference to FIGS. 1-5) supplies DC pulses at frequencies in the range of about 1 Hz to about 1000 Hz, amplitudes in the range of about ±100 to about ±3000 VDC, and pulse widths (e.g., pulse durations) in the range of about 1 μs to about 100 ms to the electrode assembly 302. The polarity of the energy delivered to the first and second arm electrodes 302a, b electrodes may be reversed during the electrical ablation therapy. For example, the polarity of the DC pulses initially delivered at amplitudes in the range of about +100 to about +3000 VDC may be reversed to amplitudes of about −100 to about −3000 VDC. Preferably, the tumor 110 may be electrically ablated with DC pulses at frequencies of about 10 Hz to about 100 Hz, amplitudes in the range of about +700 to about +1500 VDC, and pulse widths of about 10 μs to about 50 μs.

FIGS. 11A-C are side views of one embodiment of an electrical ablation device 400 shown in various stages of deployment. In one embodiment, the electrical ablation device 400 may be used in treatment of abnormal tissues or growths, such as cancers or tumors, formed in or on solid organs, BPH, and restricted gastric tissue using IRE energy. In other embodiments, electrical ablation treatment may be applied using other forms of electrical energy, such as those described herein. FIG. 11A illustrates one embodiment of the electrical ablation device 400 being deployed through the tumor 110 and the liver 112. In the illustrated embodiment, the electrical ablation device 400 comprises an electrode assembly 402 that is attachable to a solid organ such as the liver 112. In one embodiment, the electrode assembly 402 comprises a sharp distal end 404 adapted to pierce and penetrate the liver 112 and the tumor 110. The sharp distal end 404 can be inserted into one side of the liver 112, through the tumor 110, and out the opposite side of the liver 112. In one embodiment, the electrode assembly 402 comprises a first canopy electrode 402a and a second canopy electrode 402b. The first and second canopy electrodes 402a, b each comprises at least one electrically conductive portion that is formed of or coated with an electrically conductive material such as medical grade stainless steel, for example, and are coupled to the energy source 119 (previously described with reference to FIGS. 1-5) through one or more electrically conductive wires 220a, b that form the cable 106 as shown in FIG. 7C. The first and second canopy electrodes 402a, b are electrically coupled to an electrically conductive wire disposed within the cable 106 to couple the first and second canopy electrodes 402a, b to the energy source 119 previously described with reference to FIGS. 1-5. In one embodiment the first canopy electrode 402a may be configured as the anode (+) electrode coupled to the positive terminal of the energy source 119 and the second canopy electrode 402b may be configured as the cathode (−) electrode coupled to the negative terminal of the energy source 119. It will be appreciated that the polarity of the first and second canopy electrodes 402a, b may be reversed such that the first canopy electrode 402a is configured as the cathode (−) electrode and the second canopy electrode 402b is configured as the anode (+) electrode by reversing the output polarity of the energy source 119. In various other embodiments, the first and second canopy electrodes 404a, b of the electrical ablation device 400 may be coupled to the energy source 119 percutaneously through the abdominal wall 109 (FIG. 19) or wirelessly by replacing the cable 106 with the antenna 904 (FIG. 20). The antenna 904 is coupled to the first canopy electrode 404a by a first electrically conductive wire and the antenna 904 is coupled to the second canopy electrode 404b by a second electrically conductive wire.

The first and second canopy electrodes 402a, b have an umbrella-like structure such that each canopy electrode 402a, b can be independently opened and closed. In FIG. 11A, the first and second canopy electrodes 402a, b are shown in a closed position used for insertion through the tumor 110 and the liver 112. The first and second canopy electrodes 402a, b each comprise a plurality of ribs 406a, b, shown in cross-section, to support electrically conductive sheets 414a, b. The electrically conductive sheets 414a, b are attached to the respective plurality of ribs 406a, b. Each of the first and second canopy electrodes 402a, b comprises a plurality of stretchers 408a, b that are pivotally coupled to the ribs 406a, b on one end and pivotally coupled to movable runners 410a, b on the other end. The first and second canopy electrodes 402a, b may be opened and closed by slidably moving the runners 410a, b along shafts 412a, b. When the first and second canopy electrodes 402a, b are opened, the electrically conductive sheets 414a, b are stretched out in a substantially circular structure. FIG. 11D is a top-view of one embodiment of the first canopy electrode 402a of the electrical ablation device 400 shown in an open position. The second canopy electrode 402b assumes a similar structure when opened.

In the embodiment shown in FIG. 11A, the first and second canopy electrodes 402a, b are shown in a closed position. The first electrode canopy electrode 402a may be opened by slidably moving the runner 410a in direction C. The second canopy electrode 402b may be opened by slidably moving the runner 410b in direction D. A first shaft 416a is coupled to the first canopy electrode 402a and is slidably received within a second hollow shaft 416b. This allows the first and second canopy electrodes 402a, b to be pulled towards each other after they are opened to compress the liver 112. The first and second shafts 416a, b are formed of an electrically insulative material such as medical grade polyester, for example, to electrically isolate the first and second shafts 416a, b from the first and second canopy electrodes 402a, b.

Referring to FIGS. 11A-C, the illustrated embodiment of the electrical ablation device 400 is shown in use in treatment of the tumor 110 formed in the liver 112 using IRE energy. As shown in FIG. 11A, the first and second canopy electrodes 402a, b are folded in a closed position. The distal end 404 of the second canopy electrode 402a is inserted in direction C into one side of the liver 112, through the tumor 110, and out the other side of the liver 112. As shown in FIG. 11B, both the first and second canopy electrodes 402a, b are opened by slidably moving the respective runners 410a, b in the respective directions C and D as discussed above. When the first and second canopy electrodes 402a, b are opened, the stretchers 408a, b stretch out the electrically conductive sheets 414a, b. Then, the first canopy electrode 402a is pulled in direction D and the second canopy electrode 402b is pushed in direction C such that the first shaft 416a is slidably received within the second shaft 416b and the first and second canopy electrodes 402a, b are pulled adjacent to the outer surfaces of the liver 112, as shown in FIG. 11C. The first and second canopy electrodes 402a, b may be pulled towards each other to compress the portion of the liver 112 located therebetween. As shown in FIG. 11C the liver 112 may be slightly compressed such that y₂<y₁, where y₁is the pre-compressed thickness of the liver 112 and y₂is the compressed thickness of the liver 112.

With reference to FIG. 11C, the tumor 110 may be electrically ablated by applying IRE energy to the electrode assembly 402 when the first and second electrodes 402a, b are deployed. As previously discussed, the energy source 119 (previously described with reference to FIGS. 1-5) supplies DC pulses at frequencies in the range of about 1 Hz to about 1000 Hz, amplitudes in the range of about ±100 to about ±3000 VDC, and pulse widths (e.g., pulse durations) in the range of about 1 μs to about 100 ms to the first and second canopy electrodes 402a, b. The polarity of the energy delivered to the first and second canopy electrodes 402a, b may be reversed during the electrical ablation therapy. For example, the polarity of the DC pulses initially delivered at amplitudes in the range of about +100 to about +3000 VDC may be reversed to amplitudes of about −100 to about −3000 VDC. Preferably, the tumor 110 may be electrically ablated with DC pulses at frequencies of about 10 Hz to about 100 Hz, amplitudes in the range of about +700 to about +1500 VDC, and pulse widths of about 10 μs to about 50 μs.

FIG. 12 illustrates one embodiment of an electrical ablation device 500 attached to a solid organ prior to being connected to the energy source 119 (previously described with reference to FIGS. 1-5). In one embodiment, the electrical ablation device 500 may be used in treatment of abnormal tissues or growths, such as cancers or tumors, formed in or on solid organs, BPH, and restricted gastric tissue using IRE energy. In other embodiments, electrical ablation treatment may be applied using other forms of electrical energy, such as those described herein. In the embodiment illustrated in FIG. 12, the electrical ablation device 500 comprises an electrode 504. The electrode 504 is configured for attachment to a solid organ, such as the liver 112. In the embodiment illustrated in FIG. 12, the electrode 504 is attached to the liver 112. The electrode 504 may be attached to the liver 112, or any solid organ, using a variety of fasteners. The electrode 504 comprises a first plate electrode 504a and a second plate electrode 504b and a center post 504c located therebetween. The first and second plate electrodes 504a, b each comprises at least one electrically conductive portion that is formed of or coated with an electrically conductive material such as medical grade stainless steel, for example, and are electrically coupled to respective first and second conductor portions of the cable 506 to deliver electrical ablation energy to the tumor 110 from the energy source 119. The center post 504c is inserted through the tumor 110 and the first and second plate electrodes 504a, b are positioned on either side of the tumor 110 on an outer surface of the liver 112. The center post 504c is formed of an electrically insulative material such as medical grade polyester, for example, to electrically isolate the center post 504c from the first and second plate electrodes 504a, b. In one embodiment the first plate electrode 504a may be configured as the anode (+) electrode coupled to the positive terminal of the energy source 119 and the second plate electrode 504b may be configured as the cathode (−) electrode coupled to the negative terminal of the energy source 119. It will be appreciated that the polarity of the first and second plate electrodes 504a, b may be reversed such that the first plate electrode 504a is configured as the cathode (−) electrode and the second plate electrode 504b is configured as the anode (+) electrode by reversing the output polarity of the energy source 119. In various other embodiments, the first and second plate electrodes 504a, b of the electrical ablation device 500 may be coupled to the energy source 119 percutaneously through the abdominal wall 109 (FIG. 19) or wirelessly by replacing the cable 106 with the antenna 904 (FIG. 20). The antenna 904 is coupled to the first plate electrode 504a by a first electrically conductive wire and the antenna 904 is coupled to the second plate electrode 504b by a second electrically conductive wire.

In the illustrated embodiment, the first plate electrode 504a is located above the tumor 110 and the second plate electrode 504b is located below the tumor 110. The first and second plate electrodes 504a, b are configured as electrodes. The first plate electrode 504a comprises a connector 114 to couple the electrode 504 to an energy source via an endoscopically, laparoscopically, transcutaneously, or percutaneously insertable cable 506 comprising the mating plug 115 to electrically couple to the connector 114. The first and second plate electrodes 504a, b are electrically coupled to respective first and second conductor portions of the cable 506, for example. In one embodiment, the first and second plate electrodes 504a, b may be introduced endoscopically, laparoscopically, or via open surgical procedures such as a laparotomy. As previously discussed, the cable 506 also may be introduced into the stomach 108 trans-orally through the access or working channel of the endoscope. In the illustrated embodiment, the cable 506 is inserted percutaneously through the abdominal wall 109.

With reference to FIG. 12, the tumor 110 may be electrically ablated by applying IRE energy to the electrode 504 when the first and second plate electrodes 504a, b are deployed. As previously discussed, the energy source 119 (previously described with reference to FIGS. 1-5) supplies DC pulses at frequencies in the range of about 1 Hz to about 1000 Hz, amplitudes in the range of about ±100 to about ±3000 VDC, and pulse widths (e.g., pulse durations) in the range of about 1 μs to about 100 ms to the first and second plate electrodes 504a, b of the electrode 504. The polarity of the energy delivered to the first and second plate electrodes 504a, b of the electrode 504 may be reversed during the electrical ablation therapy. For example, the polarity of the DC pulses initially delivered at amplitudes in the range of about +100 to about +3000 VDC may be reversed to amplitudes of about −100 to about −3000 VDC. Preferably, the tumor 110 may be electrically ablated with DC pulses at frequencies of about 10 Hz to about 100 Hz, amplitudes in the range of about +700 to about +1500 VDC, and pulse widths of about 10 μs to about 50 μs. The tumor 110 may be monitored over time (weeks) to observe shrinkage. The treatment may be repeated until the tumor 110 disappears.

FIG. 13 illustrates one embodiment of an electrical ablation device 600. In the illustrated embodiment, the electrical ablation device 600 comprises a balloon electrode 602 that can be inserted into the uterine cavity 638 (FIGS. 14A-B, 15A) for the treatment of menorrhagia using IRE energy. In other embodiments, electrical ablation treatment may be applied using other forms of electrical energy, such as those described herein. In other embodiments, the electrode may be implemented as a sponge or similar structure. In FIG. 13, there is shown a lateral cross-sectional view of the electrical ablation device 600. In one embodiment, the electrical ablation device 600 is primarily intended for non-surgical entry into the uterine cavity 638 of a female although one of ordinary skill in the art will recognize its usefulness in other related procedures. The electrical ablation device 600 has an elongate tubular body 610 extending from a distal end 612 to a proximal end 614. Located on the marginal distal end 612 of the body 610 is an inflatable intracervical/intrauterine balloon electrode 602. As shown in FIG. 13, the balloon electrode 602 is in a deflated state. A connector 628 for coupling the energy source 119 to the electrical ablation device 600 is located at a proximal end 620 of a conduit 604, which will be described in greater detail below.

In one embodiment, the electrical ablation device 600 also comprises an inflation fluid line 616 having a distal 622, which terminates within the body 610, and a proximal end 620. The inflation fluid line 616 enters the body 610 at a fluid line coupler 630. The proximal end 620 of the inflation fluid line 616 may be coupled to a conventional inline rotary valve (not shown) to control the flow of inflation fluid. A proximal end of the inline rotary valve is removably coupled to a conventional inflation syringe 626 (FIGS. 15A-B). A cylindrical collar member 632 is slidably mounted on the tubular body 610 between the balloon electrode 602 and the fluid line coupler 630. The collar member 632 comprises an outwardly extending circumferential flange 634 at its distal end.

As shown, the inner conduit 604 defines a working lumen 606 is disposed within the body 610 and extends the entire length of the body 610 from the distal end 612 to the proximal end 614. The working lumen 606 of the inner conduit 604 provides an electrical communication path for the introduction of one or more electrically conductive wires 608 for delivering electrical energy from the energy source 119 to the balloon electrode 602. The one ore more conductors 608 may be electrically coupled to the balloon electrode 602 to convey electrical energy from the energy source 119 thereto.

The inflation fluid line 616 defines an inflation lumen 618. The inflation lumen 618 starts at the proximal end 620 of the inflation fluid line 616 and extends therethrough to the distal end 622 thereof. The inflation lumen 618 fluidically communicates with the interior of the balloon electrode 602 via an aperture 624. The inflation lumen 618 of the inflation fluid line 616 provides a fluid communication path for inflating the balloon electrode 602 with a fluid 629 (FIG. 15A). The fluid 629 may be either saline or air or other suitable electrically conductive inflation fluid. An inline rotary valve (not shown) may operate to maintain the balloon electrode 602 in the inflated state after inflation by the inflation syringe 626 (FIGS. 15A, 15B). A port 639 may be defined at the distal end of the working lumen 406 to provide a fluid communication path between the working lumen 406 and the external portion of the balloon electrode 602 to deliver fluids into the hollow body lumen (e.g., the uterine cavity 638) outside of the balloon electrode 602.

FIGS. 14A and 14B show the progression of one embodiment of the electrical ablation device 600 penetrating through the cervix 636 and insertion into the uterine cavity 638. FIG. 14A illustrates the balloon electrode 602 in a deflated state inserted into the cervix 636. FIG. 14B illustrates the balloon electrode 602 inserted in the uterine cavity 638 in a partially inflated state. Once the balloon electrode 602 is inserted into the uterine cavity 638, the balloon electrode 602 may be fully inflated.

In FIG. 15A, the electrical ablation device 600 is shown in use entering the cervix 636 with the balloon electrode 602 in a deflated state. Once inserted through the cervix 636 and into the uterine cavity 638, as shown in FIG. 15B, the balloon electrode 602 is inflated by pushing the plunger 640 into the body 642 of the inflation syringe 626. The balloon electrode 602 is inflated with the fluid 629. Once the balloon electrode 602 is inflated, an inline rotary valve (not shown) may be rotated into a “closed position” to prevent communication between the inflation syringe 626 and the inflation lumen 618 (FIG. 13). When it is desirable to deflate the balloon electrode 602, the inline rotary valve may be rotated into an “open position” to reestablish communication between the inflation syringe 626 and the inflation lumen 618. To deflate the balloon electrode 602, the plunger 640 is pulled toward the proximal end of the body 642 of the inflation syringe 626. A conductive fluid may be injected around the balloon electrode 602 to expand the zone of treatment. The conductive fluid may be delivered through the port 639 (FIG. 13) into the uterine cavity 638 to expand the zone of treatment.

The various components of the electrical ablation device 600 are made from conventional materials such as nylon, polyethylene, or a composite. In one embodiment, the intracervical/intrauterine balloon electrode 602 is made from or comprises an electrically conductive material to transmit electrical energy from the energy source 119 to the internal walls 644 of the uterine cavity 638 for applying electrical ablation therapy thereto. In another embodiment, the intracervical/intrauterine balloon electrode 602 may be made from a medical grade polyurethane material comprising an electrically conductive coating on an outer surface thereof. In another embodiment, the balloon electrode 602 may be made from an electrically conductive material. In yet another embodiment, the balloon electrode 602 may be made from an electrically insulative material, such as the medical grade polyurethane, and inflated with a conductive fluid (e.g., saline) to form the electrically conductive portion of the balloon electrode 602. In one embodiment the balloon electrode 602 may be configured as the anode (+) electrode coupled to the positive terminal of the energy source 119 and in another embodiment the balloon electrode 602 may be configured as the cathode (−) electrode coupled to the negative terminal of the energy source 119. It will be appreciated that the polarity of the balloon electrode 602 may be reversed by reversing the output polarity of the energy source 119. In one embodiment, the balloon electrode 602 may be configured as either the anode (+) or the cathode (−) relative to a reference polarity. For example, the balloon electrode 602 may be configured as the cathode (+) coupled to the positive output of the energy source 119 relative to a ground plane cathode (−) located beneath the patient and coupled to the negative terminal of the energy source 119.

In the embodiment illustrated in FIGS. 14A-B and 15A-B, the electrical ablation device 600 is configured for use as an intrauterine device for treating menorrhagia through the use of electrical energy. In one embodiment, the balloon electrode 602 applies IRE energy supplied by the energy source 119. As previously described, IRE provides an effective method for destroying cells while avoiding some of the negative complications of heat-inducing therapies. Namely, IRE destroys cells without the use of heat and does not destroy cellular support structure or regional vasculature. In the illustrated embodiment, the balloon electrode 602 can be inserted into the uterine cavity 638 and once placed therein the balloon electrode 602 can be expanded or inflated with the fluid 629 to make substantially complete contact with the uterine wall 644.

After the balloon electrode 602 is inflated, electrical ablation energy is supplied by the energy source 119 to electrically ablate the internal walls 644 of the uterine cavity 638 to treat menorrhagia by applying IRE energy to the balloon electrode 602. As previously discussed, the energy source 119 (previously described with reference to FIGS. 1-5) supplies DC pulses at frequencies in the range of about 1 Hz to about 1000 Hz, amplitudes in the range of about ±100 to about ±3000 VDC, and pulse widths (e.g., pulse durations) in the range of about 1 μs to about 100 ms to the balloon electrode 602. The polarity of the energy delivered to the balloon electrode 602 may be reversed during the electrical ablation therapy. For example, the polarity of the DC pulses initially delivered at amplitudes in the range of about +100 to about +3000 VDC may be reversed to amplitudes of about −100 to about −3000 VDC. Preferably, the internal walls 644 of the uterine cavity 638 may be electrically ablated with DC pulses at frequencies of about 10 Hz to about 100 Hz, amplitudes in the range of about +700 to about +1500 VDC, and pulse widths of about 10 μs to about 50 μs. Multiple placements of the balloon electrode 602 can be performed to treat large areas of the uterus. A conductive fluid may be injected around the balloon electrode 602 to expand the zone of treatment for a given irreversible electroporation treatment. The menorrhagia may be monitored over time (weeks) to observe the effectiveness of the electrical ablation therapy. The treatment may be repeated until the menorrhagia disappears.

FIG. 16 illustrates one embodiment of an electrical ablation device 700 for removing excess skin 702 using IRE energy. In other embodiments, electrical ablation treatment may be applied using other forms of electrical energy, such as those described herein. The electrical ablation device 700 may be used in minimally invasive therapy for removal of the excess skin 702 following excess weight loss due to bariatric surgery. This therapy involves the administration of IRE energy pulses to excess skin 702 at various sites on a patient's body. As previously described with reference to FIGS. 1-5, the IRE energy pulses may be supplied by the energy source 119. In the embodiment illustrated in FIG. 16, the electrical ablation device 700 comprises needle electrodes 704a, 704b that may be inserted through the skin 702. The needle electrodes 704a, b each comprises at least one electrically conductive portion that is formed of or coated with an electrically conductive material such as medical grade stainless steel, for example. In one embodiment the first needle electrode 704a may be configured as the anode (+) electrode coupled to the positive terminal of the energy source 119 and the second needle electrode 704b may be configured as the cathode (−) electrode coupled to the negative terminal of the energy source 119. It will be appreciated that the polarity of the first and second needle electrodes 704a, b may be reversed such that the first needle electrode 704a is configured as the cathode (−) electrode and the second needle electrode 704b is configured as the anode (+) electrode by reversing the output polarity of the energy source 119. It will be appreciated that a plurality of needle electrodes may be employed. Once the needle electrodes 704a, b are inserted at the appropriate level below the outer epidermis layer of the skin 702, IRE energy pulses may be administered to the needle electrodes 704a, b by the energy source 119 to destroy the cells of the epidermis, dermis, and subcutis layers of the skin 702. The needle electrodes 704a, b may be moved to various locations on the excess skin 702 flap, and the treatment repeated.

The therapeutic treatments administered using the embodiments of the electrical ablation device 700 illustrated in FIG. 16 result in a reduction in the surface area of the skin 702. The therapy may be administered over several weeks or months, with each therapy resulting in the gradual removal of the excess skin 702. The electrical ablation energy is supplied by the energy source 119. As previously discussed, the energy source 119 (previously described with reference to FIGS. 1-5) supplies DC pulses at frequencies in the range of about 1 Hz to about 1000 Hz, amplitudes in the range of about ±100 to about ±3000 VDC, and pulse widths (e.g., pulse durations) in the range of about 1 μs to about 100 ms to the needle electrodes 704a, b. The polarity of the energy delivered to the needle electrodes 704a, b may be reversed during the electrical ablation therapy. For example, the polarity of the DC pulses initially delivered at amplitudes in the range of about +100 to about +3000 VDC may be reversed to amplitudes of about −100 to about −3000 VDC. Preferably, the excess skin 702 may be electrically ablated with DC pulses at frequencies of about 10 Hz to about 100 Hz, amplitudes in the range of about +700 to about +1500 VDC, and pulse widths of about 10 μs to about 50 μs. Multiple placements of the needle electrodes 704a, b can be performed to treat large areas of the excess skin 702.

FIG. 17 illustrates one embodiment of an electrical ablation device 800 for removing excess skin 702. In one embodiment, the excess skin 702 may be removed using IRE energy. In other embodiments, electrical ablation treatment may be applied using other forms of electrical energy, such as those described herein. The electrical ablation device 800 may be used in minimally invasive therapy for removal of the excess skin 702 that normally follows excess weight loss due to bariatric surgery. In the embodiment illustrated in FIG. 17, first and second electrodes 802a, 802b are configured as rollers (first and second roller electrodes 802a, b). The first and second electrodes 802a, b have a substantially circular or disk-like body defining a hub 812 and are arranged to rotate about an axis. The IRE energy pulses from the energy source 119 (previously described with reference to FIGS. 1-5) are administered as the first and second roller electrodes 802a, b move over the patient's skin 702. The IRE energy destroys the cells in the epidermis and the dermis layers of the skin 702. In one embodiment the first roller electrode 802a may be configured as the anode (+) electrode coupled to the positive terminal of the energy source 119 and the second roller electrode 802b may be configured as the cathode (−) electrode coupled to the negative terminal of the energy source 119. It will be appreciated that the polarity of the first and second roller electrodes 802a, b may be reversed such that the first roller electrode 802a is configured as the cathode (−) electrode and the second roller electrode 802b is configured as the anode (+) electrode by reversing the output polarity of the energy source 119. In one embodiment, both the first and second roller electrodes 802a, b may be coupled to the same polarity and may be configured as the anode (+) or the cathode (−) relative to a reference polarity. For example, the first and second roller electrodes 802a, b may be configured as the cathode (+) coupled to the positive output of the energy source 119 relative to a ground plane cathode (−) located beneath the patient and coupled to the negative terminal of the energy source 119.

FIG. 18 is a detail cross-sectional view of one embodiment of the electrode 802a. Those skilled in the art will appreciate that the roller electrode 802b may be constructed in a similar fashion. As shown in FIG. 18, the roller electrode 802a comprises a body having at least one electrically conductive portion at an outer surface thereof that is formed of or coated with an electrically conductive material (e.g., copper, aluminum, brass, steel, medical grade stainless steel). The roller electrode 802a rotates about a cylindrical bearing 804 positioned within the hub 812. The cylindrical bearing 804 is formed of an electrically conductive material and is in electrical communication with the electrically conductive portion of the roller electrode 802a body. An electrically insulative sleeve 806 formed of medical grade polyester, for example, is positioned between the cylindrical bearing 804 and a shaft 808. The shaft 808 is received within the hub 812 and defines as an axis of rotation for the roller electrode 802a. An electrically conductive wire 810 is electrically coupled to the bearing 804 and thus to the roller electrode 802a. Electrical energy from the energy source 119 is conducted via the conductor 810 to the roller electrode 802a. The embodiments of the roller electrodes 802a, b are not limited in this context.

The therapeutic treatments administered using the embodiments of the electrical ablation device 800 illustrated in FIGS. 17 and 18 result in a reduction in the surface area of the skin 702. The therapy may be administered over several weeks or months, with each therapy resulting in the gradual removal of the excess skin 702. The electrical ablation energy is supplied by the energy source 119. As previously discussed, the energy source 119 (previously described with reference to FIGS. 1-5) supplies DC pulses at frequencies in the range of about 1 Hz to about 1000 Hz, amplitudes in the range of about ±100 to about ±3000 VDC, and pulse widths (e.g., pulse durations) in the range of about 1 μs to about 100 ms to the roller electrodes 802a, b. The polarity of the energy delivered to the roller electrodes 802a, b may be reversed during the electrical ablation therapy. For example, the polarity of the DC pulses initially delivered at amplitudes in the range of about +100 to about +3000 VDC may be reversed to amplitudes of about −100 to about −3000 VDC. Preferably, the excess skin 702 may be electrically ablated with DC pulses at frequencies of about 10 Hz to about 100 Hz, amplitudes in the range of about +700 to about +1500 VDC, and pulse widths of about 10 μs to about 50 μs. Multiple placements of the roller electrodes 802a, b can be performed to treat large areas of the excess skin 702.

FIG. 20 illustrates one embodiment of a wireless electrical ablation device 900 shown in use. The electrical ablation device 900 comprises one or more electrodes 902 connected to an antenna 904. In various embodiments, the one or more electrodes 902 may be configured as any one of the previously discussed electrodes 100, 200, 300, 400, 500, 600. In one embodiment, the energy source 119 may comprise a wireless transmitter 906 configured to deliver energy 910 to the one or more electrodes 902 via an antenna 908. The energy source 119 transmits the energy 910 through the transmitting antenna 908, which is received by the antenna 904, thus eliminating the need to perforate the hollow body lumen or the patient's skin. The embodiments are not limited in this context.

The various embodiments of the electrical ablation devices and techniques described herein may be employed in electrical ablation therapy of tissue. Embodiments of the electrical ablation devices and techniques described herein may be employed in treatment or removal of diseased tissue, restricted gastric tissue, adipose tissue, abnormal tissue masses, tumors, lesions, adhesions, BPH, and menorrhagia, among others, located inside the patient's body using electrical ablation energy. Other embodiments of the electrical ablation devices described herein may be employed in treatment or removal of excess skin following bariatric surgery using electrical ablation energy.

The embodiments of the electrical ablation devices described herein may be introduced inside a patient using minimally invasive or open surgical techniques. In some instances it may be advantageous to introduce the electrical ablation devices inside the patient using a combination of minimally invasive and open surgical techniques. Minimally invasive techniques provide more accurate and effective access to the treatment region for diagnostic and treatment procedures. To reach internal treatment regions within the patient, the electrical ablation devices described herein may be inserted through natural openings of the body such as the mouth, anus, and/or vagina, for example. Minimally invasive procedures performed by the introduction of various medical devices into the patient through a natural opening of the patient are known in the art as Natural Orifice Translumenal Endoscopic Surgery (NOTES™) procedures. Surgical devices, such as an electrical ablation devices, may be introduced to the treatment region through the working channels of the endoscope to perform key surgical activities (KSA), including, for example, electrical ablation of tissues using IRE energy. Some portions of the electrical therapy ablation devices may be introduced to the tissue treatment region percutaneously or through small—keyhole—incisions.

Endoscopic minimally invasive surgical and diagnostic medical procedures are used to evaluate and treat internal organs by inserting a small tube into the body. The endoscope may have a rigid or a flexible tube. A flexible endoscope may be introduced either through a natural body opening (e.g., mouth, anus, and/or vagina). A rigid endoscope may be introduced via trocar through a relatively small—keyhole—incision incisions (usually 0.5-1.5 cm). The endoscope can be used to observe surface conditions of internal organs, including abnormal or diseased tissue such as lesions and other surface conditions and capture images for visual inspection and photography. The endoscope may be adapted and configured with working channels for introducing medical instruments to the treatment region for taking biopsies, retrieving foreign objects, and/or performing surgical procedures.

Once an electrical ablation device is inserted in the human body internal organs may be reached using trans-organ or translumenal surgical procedures. The electrical ablation device may be advanced to the treatment site using endoscopic translumenal access techniques to perforate a lumen, and then, advance the electrical ablation device and the endoscope into the peritoneal cavity. Translumenal access procedures for perforating a lumen wall, inserting, and advancing an endoscope therethrough, and pneumoperitoneum devices for insufflating the peritoneal cavity and closing or suturing the perforated lumen wall are well known. During a translumenal access procedure, a puncture must be formed in the stomach wall or in the gastrointestinal tract to access the peritoneal cavity. One device often used to form such a puncture is a needle knife which is inserted through the working channel of the endoscope, and which utilizes energy to penetrate through the tissue. A guidewire is then feed through the endoscope and is passed through the puncture in the stomach wall and into the peritoneal cavity. The needle knife is removed, leaving the guidewire as a placeholder. A balloon catheter is then passed over the guidewire and through the working channel of the endoscope to position the balloon within the opening in the stomach wall. The balloon can then be inflated to increase the size of the opening, thereby enabling the endoscope to push against the rear of the balloon and to be feed through the opening and into the peritoneal cavity. Once the endoscope is positioned within the peritoneal cavity, numerous procedures can be performed through the working channel of the endoscope.

The endoscope may be connected to a video camera (single chip or three chip) and may be attached to a fiber-optic cable system connected to a “cold” light source (halogen or xenon), to illuminate the operative field. The video camera provides a direct line-of-sight view of the treatment region. The abdomen is usually insufflated with carbon dioxide (CO₂) gas to create a working and viewing space. The abdomen is essentially blown up like a balloon (insufflated), elevating the abdominal wall above the internal organs like a dome. CO₂gas is used because it is common to the human body and can be removed by the respiratory system if it is absorbed through tissue.

Once the electrical ablation devices are located at the target site, the diseased tissue may be electrically ablated or destroyed using the various embodiments of electrodes discussed herein. The placement and location of the electrodes can be important for effective and efficient electrical ablation therapy. For example, the electrodes may be positioned proximal to a treatment region (e.g., target site or worksite) either endoscopically or transcutaneously (percutaneously). In some implementations, it may be necessary to introduce the electrodes inside the patient using a combination of endoscopic, transcutaneous, and/or open techniques. The electrodes may be introduced to the tissue treatment region through a working channel of the endoscope, an overtube, or a trocar and, in some implementations, may be introduced through percutaneously or through small—keyhole—incisions.

Preferably, the various embodiments of the devices described herein will be processed before surgery. First, a new or used instrument is obtained and if necessary cleaned. The instrument can then be sterilized. In one sterilization technique, the instrument is placed in a closed and sealed container, such as a plastic or TYVEK® bag. The container and instrument are then placed in a field of radiation that can penetrate the container, such as gamma radiation, x-rays, or high-energy electrons. The radiation kills bacteria on the instrument and in the container. The sterilized instrument can then be stored in the sterile container. The sealed container keeps the instrument sterile until it is opened in the medical facility.

It is preferred that the device is sterilized. This can be done by any number of ways known to those skilled in the art including beta or gamma radiation, ethylene oxide, steam.

Although the various embodiments of the devices have been described herein in connection with certain disclosed embodiments, many modifications and variations to those embodiments may be implemented. For example, different types of end effectors may be employed. Also, where materials are disclosed for certain components, other materials may be used. The foregoing description and following claims are intended to cover all such modification and variations.

Any patent, publication, or other disclosure material, in whole or in part, said to be incorporated by reference herein is incorporated herein only to the extent that the incorporated materials does not conflict with existing definitions, statements, or other disclosure material set forth in this disclosure. As such, and to the extent necessary, the disclosure as explicitly set forth herein supersedes any conflicting material incorporated herein by reference. Any material, or portion thereof, said to be incorporated by reference herein, but which conflicts with existing definitions, statements, or other disclosure material set forth herein will only be incorporated to the extent that no conflict arises between that incorporated material and the existing disclosure material.

Claims

1. An electrical ablation apparatus, comprising: a connector configured to receive electrical energy from an energy source, the connector selectively connectable to a wire extending from the energy source;a fastener coupled to the connector, the fastener configured for attachment through a tissue wall; anda first electrode comprising at least one electrically conductive portion coupled to the connector by a first electrically conductive wire.
2. The electrical ablation apparatus of claim 1, wherein the connector comprises: a body comprising at least one recess for receiving at least one corresponding tab;at least one terminal;a first flange comprising at least one opening for receiving a suture or tag for attaching the connector to the tissue wall;a second flange comprising at least one opening for receiving a suture or tag for attaching the connector to the tissue wall; anda hollow shaft connecting the first and second flanges, the hollow shaft defining a longitudinal opening for receiving the at least one electrically conductive wire therethrough, wherein a first end of the at least one electrically conductive wire is connected to the at least one terminal.
3. The electrical ablation apparatus of claim 1, wherein the first electrode comprises a tapered body.
4. The electrical ablation apparatus of claim 3, wherein the tapered body comprises ridges formed on an outer surface to penetrate and attach the at least one electrode proximal to tissue to be ablated.
5. The electrical ablation apparatus of claim 1, wherein the first electrode comprises a helical body to penetrate and attach the first electrode proximal to tissue to be ablated.
6. The electrical ablation apparatus of claim 1, comprising: a second electrode comprising at least one electrically conductive portion coupled to the connector by a second electrically conductive wire.

US Referenced Citations (1204)

Number	Name	Date	Kind
645576	Tesla	Mar 1900	A
649621	Tesla	May 1900	A
787412	Tesla	Apr 1905	A
1127948	Wappler	Feb 1915	A
1482653	Lilly	Feb 1924	A
1625602	Gould et al.	Apr 1927	A
2028635	Wappler	Jan 1936	A
2031682	Wappler et al.	Feb 1936	A
2113246	Wappler	Apr 1938	A
2155365	Rankin	Apr 1939	A
2191858	Moore	Feb 1940	A
2196620	Attarian	Apr 1940	A
2388137	Graumlich	Oct 1945	A
2493108	Casey, Jr.	Jan 1950	A
2504152	Riker et al.	Apr 1950	A
2938382	De Graaf	May 1960	A
2952206	Becksted	Sep 1960	A
3069195	Buck	Dec 1962	A
3170471	Schnitzer	Feb 1965	A
3435824	Gamponia	Apr 1969	A
3470876	Barchilon	Oct 1969	A
3595239	Petersen	Jul 1971	A
3669487	Roberts et al.	Jun 1972	A
3746881	Fitch et al.	Jul 1973	A
3799672	Vurek	Mar 1974	A
3854473	Matsuo	Dec 1974	A
3946740	Bassett	Mar 1976	A
3948251	Hosono	Apr 1976	A
3994301	Agris	Nov 1976	A
4011872	Komiya	Mar 1977	A
4012812	Black	Mar 1977	A
4085743	Yoon	Apr 1978	A
4164225	Johnson et al.	Aug 1979	A
4178920	Cawood, Jr. et al.	Dec 1979	A
4207873	Kruy	Jun 1980	A
4235238	Ogiu et al.	Nov 1980	A
4258716	Sutherland	Mar 1981	A
4269174	Adair	May 1981	A
4278077	Mizumoto	Jul 1981	A
4285344	Marshall	Aug 1981	A
4311143	Komiya	Jan 1982	A
4329980	Terada	May 1982	A
4396021	Baumgartner	Aug 1983	A
4406656	Hattler et al.	Sep 1983	A
4452246	Bader et al.	Jun 1984	A
4461281	Carson	Jul 1984	A
4491132	Aikins	Jan 1985	A
4527331	Lasner et al.	Jul 1985	A
4527564	Eguchi et al.	Jul 1985	A
4538594	Boebel et al.	Sep 1985	A
D281104	Davison	Oct 1985	S
4569347	Frisbie	Feb 1986	A
4580551	Siegmund et al.	Apr 1986	A
4646722	Silverstein et al.	Mar 1987	A
4653476	Bonnet	Mar 1987	A
4655219	Petruzzi	Apr 1987	A
4669470	Brandfield	Jun 1987	A
4671477	Cullen	Jun 1987	A
4685447	Iversen et al.	Aug 1987	A
4711240	Goldwasser et al.	Dec 1987	A
4712545	Honkanen	Dec 1987	A
4721116	Schintgen et al.	Jan 1988	A
4733662	DeSatnick et al.	Mar 1988	A
D295894	Sharkany et al.	May 1988	S
4763669	Jaeger	Aug 1988	A
4770188	Chikama	Sep 1988	A
4815450	Patel	Mar 1989	A
4823794	Pierce	Apr 1989	A
4829999	Auth	May 1989	A
4867140	Hovis et al.	Sep 1989	A
4873979	Hanna	Oct 1989	A
4880015	Nierman	Nov 1989	A
4911148	Sosnowski et al.	Mar 1990	A
4926860	Stice et al.	May 1990	A
4938214	Specht et al.	Jul 1990	A
4950273	Briggs	Aug 1990	A
4950285	Wilk	Aug 1990	A
4960133	Hewson	Oct 1990	A
4977887	Gouda	Dec 1990	A
4979950	Transue et al.	Dec 1990	A
4984581	Stice	Jan 1991	A
5007917	Evans	Apr 1991	A
5010876	Henley et al.	Apr 1991	A
5020514	Heckele	Jun 1991	A
5020535	Parker et al.	Jun 1991	A
5025778	Silverstein et al.	Jun 1991	A
5033169	Bindon	Jul 1991	A
5037433	Wilk et al.	Aug 1991	A
5041129	Hayhurst et al.	Aug 1991	A
5046513	Gatturna et al.	Sep 1991	A
5050585	Takahashi	Sep 1991	A
5052372	Shapiro	Oct 1991	A
5065516	Dulebohn	Nov 1991	A
5066295	Kozak et al.	Nov 1991	A
5123913	Wilk et al.	Jun 1992	A
5123914	Cope	Jun 1992	A
5133727	Bales et al.	Jul 1992	A
5147374	Fernandez	Sep 1992	A
5174300	Bales et al.	Dec 1992	A
5176126	Chikama	Jan 1993	A
5190050	Nitzsche	Mar 1993	A
5190555	Wetter et al.	Mar 1993	A
5192284	Pleatman	Mar 1993	A
5201752	Brown et al.	Apr 1993	A
5201908	Jones	Apr 1993	A
5203785	Slater	Apr 1993	A
5203787	Noblitt et al.	Apr 1993	A
5209747	Knoepfler	May 1993	A
5217003	Wilk	Jun 1993	A
5217453	Wilk	Jun 1993	A
5219357	Honkanen et al.	Jun 1993	A
5219358	Bendel et al.	Jun 1993	A
5222362	Maus et al.	Jun 1993	A
5222965	Haughton	Jun 1993	A
5234437	Sepetka	Aug 1993	A
5234453	Smith et al.	Aug 1993	A
5235964	Abenaim	Aug 1993	A
5242456	Nash et al.	Sep 1993	A
5246424	Wilk	Sep 1993	A
5259366	Reydel et al.	Nov 1993	A
5263958	deGuillebon et al.	Nov 1993	A
5273524	Fox et al.	Dec 1993	A
5275607	Lo et al.	Jan 1994	A
5284128	Hart	Feb 1994	A
5284162	Wilk	Feb 1994	A
5287845	Faul et al.	Feb 1994	A
5290299	Fain et al.	Mar 1994	A
5290302	Pericic	Mar 1994	A
5295977	Cohen et al.	Mar 1994	A
5297536	Wilk	Mar 1994	A
5301061	Nakada et al.	Apr 1994	A
5312333	Churinetz et al.	May 1994	A
5312351	Gerrone	May 1994	A
5312416	Spaeth et al.	May 1994	A
5312423	Rosenbluth et al.	May 1994	A
5320636	Slater	Jun 1994	A
5325845	Adair	Jul 1994	A
5330471	Eggers	Jul 1994	A
5330486	Wilk	Jul 1994	A
5330488	Goldrath	Jul 1994	A
5330496	Alferness	Jul 1994	A
5330502	Hassler et al.	Jul 1994	A
5331971	Bales et al.	Jul 1994	A
5334198	Hart et al.	Aug 1994	A
5344428	Griffiths	Sep 1994	A
5350391	Iacovelli	Sep 1994	A
5352184	Goldberg et al.	Oct 1994	A
5352222	Rydell	Oct 1994	A
5354302	Ko	Oct 1994	A
5354311	Kambin et al.	Oct 1994	A
5356408	Rydell	Oct 1994	A
5364408	Gordon	Nov 1994	A
5364410	Failla et al.	Nov 1994	A
5366466	Christian et al.	Nov 1994	A
5366467	Lynch et al.	Nov 1994	A
5368605	Miller, Jr.	Nov 1994	A
5370647	Graber et al.	Dec 1994	A
5370679	Atlee, III	Dec 1994	A
5374273	Nakao et al.	Dec 1994	A
5374275	Bradley et al.	Dec 1994	A
5374277	Hassler	Dec 1994	A
5377695	An Haack	Jan 1995	A
5383877	Clarke	Jan 1995	A
5383888	Zvenyatsky et al.	Jan 1995	A
5386817	Jones	Feb 1995	A
5391174	Weston	Feb 1995	A
5392789	Slater et al.	Feb 1995	A
5395386	Slater	Mar 1995	A
5401248	Bencini	Mar 1995	A
5403328	Shallman	Apr 1995	A
5403342	Tovey et al.	Apr 1995	A
5403348	Bonutti	Apr 1995	A
5405073	Porter	Apr 1995	A
5405359	Pierce	Apr 1995	A
5409478	Gerry et al.	Apr 1995	A
5417699	Klein et al.	May 1995	A
5423821	Pasque	Jun 1995	A
5433721	Hooven et al.	Jul 1995	A
5439471	Kerr	Aug 1995	A
5439478	Palmer	Aug 1995	A
5441059	Dannan	Aug 1995	A
5441499	Fritzsch	Aug 1995	A
5443463	Stern et al.	Aug 1995	A
5445638	Rydell et al.	Aug 1995	A
5449021	Chikama	Sep 1995	A
5456667	Ham et al.	Oct 1995	A
5456684	Schmidt et al.	Oct 1995	A
5458131	Wilk	Oct 1995	A
5458583	McNeely et al.	Oct 1995	A
5460168	Masubuchi et al.	Oct 1995	A
5460629	Shlain et al.	Oct 1995	A
5462561	Voda	Oct 1995	A
5465731	Bell et al.	Nov 1995	A
5467763	McMahon et al.	Nov 1995	A
5468250	Paraschac et al.	Nov 1995	A
5470308	Edwards et al.	Nov 1995	A
5470320	Tiefenbrun et al.	Nov 1995	A
5478347	Aranyi	Dec 1995	A
5480404	Kammerer et al.	Jan 1996	A
5482054	Slater et al.	Jan 1996	A
5484451	Akopov et al.	Jan 1996	A
5489256	Adair	Feb 1996	A
5496347	Hashiguchi et al.	Mar 1996	A
5499990	Schülken et al.	Mar 1996	A
5499992	Meade et al.	Mar 1996	A
5501692	Riza	Mar 1996	A
5503616	Jones	Apr 1996	A
5505686	Willis et al.	Apr 1996	A
5507755	Gresl et al.	Apr 1996	A
5511564	Wilk	Apr 1996	A
5514157	Nicholas et al.	May 1996	A
5522829	Michalos	Jun 1996	A
5522830	Aranyi	Jun 1996	A
5527321	Hinchliffe	Jun 1996	A
5536248	Weaver et al.	Jul 1996	A
5540648	Yoon	Jul 1996	A
5554151	Hinchliffe	Sep 1996	A
5555883	Avitall	Sep 1996	A
5558133	Bortoli et al.	Sep 1996	A
5562693	Devlin et al.	Oct 1996	A
5569243	Kortenbach et al.	Oct 1996	A
5569298	Schnell	Oct 1996	A
5573540	Yoon	Nov 1996	A
5578030	Levin	Nov 1996	A
5582611	Tsuruta et al.	Dec 1996	A
5582617	Klieman et al.	Dec 1996	A
5584845	Hart	Dec 1996	A
5591179	Edelstein	Jan 1997	A
5593420	Eubanks, Jr et al.	Jan 1997	A
5595562	Grier	Jan 1997	A
5597378	Jervis	Jan 1997	A
5601573	Fogelberg et al.	Feb 1997	A
5601588	Tonomura et al.	Feb 1997	A
5604531	Iddan et al.	Feb 1997	A
5607389	Edwards et al.	Mar 1997	A
5607450	Zvenyatsky et al.	Mar 1997	A
5613975	Christy	Mar 1997	A
5618303	Marlow et al.	Apr 1997	A
5620415	Lucey et al.	Apr 1997	A
5624399	Ackerman	Apr 1997	A
5624431	Gerry et al.	Apr 1997	A
5626578	Tihon	May 1997	A
5628732	Antoon, Jr. et al.	May 1997	A
5630782	Adair	May 1997	A
5643283	Younker	Jul 1997	A
5643292	Hart	Jul 1997	A
5643294	Tovey et al.	Jul 1997	A
5644798	Shah	Jul 1997	A
5645083	Essig et al.	Jul 1997	A
5645565	Rudd et al.	Jul 1997	A
5649372	Souza	Jul 1997	A
5653677	Okada et al.	Aug 1997	A
5653690	Booth et al.	Aug 1997	A
5653722	Kieturakis	Aug 1997	A
5662663	Shallman	Sep 1997	A
5669875	van Eerdenburg	Sep 1997	A
5681324	Kammerer et al.	Oct 1997	A
5681330	Hughett et al.	Oct 1997	A
5685820	Riek et al.	Nov 1997	A
5690656	Cope et al.	Nov 1997	A
5690660	Kauker et al.	Nov 1997	A
5695448	Kimura et al.	Dec 1997	A
5695505	Yoon	Dec 1997	A
5695511	Cano et al.	Dec 1997	A
5700275	Bell et al.	Dec 1997	A
5702438	Avitall	Dec 1997	A
5704892	Adair	Jan 1998	A
5709708	Thal	Jan 1998	A
5716326	Dannan	Feb 1998	A
5730740	Wales et al.	Mar 1998	A
5735849	Baden et al.	Apr 1998	A
5741234	Aboul-Hosn	Apr 1998	A
5741278	Stevens	Apr 1998	A
5741285	McBrayer et al.	Apr 1998	A
5746759	Meade et al.	May 1998	A
5749881	Sackier et al.	May 1998	A
5749889	Bacich et al.	May 1998	A
5752951	Yanik	May 1998	A
5755731	Grinberg	May 1998	A
5766167	Eggers et al.	Jun 1998	A
5766170	Eggers	Jun 1998	A
5766205	Zvenyatsky et al.	Jun 1998	A
5769849	Eggers	Jun 1998	A
5779701	McBrayer et al.	Jul 1998	A
5779716	Cano et al.	Jul 1998	A
5779727	Orejola	Jul 1998	A
5782859	Nicholas et al.	Jul 1998	A
5782866	Wenstrom, Jr.	Jul 1998	A
5791022	Bohman	Aug 1998	A
5792113	Kramer et al.	Aug 1998	A
5792153	Swain et al.	Aug 1998	A
5792165	Klieman et al.	Aug 1998	A
5797835	Green	Aug 1998	A
5797928	Kogasaka	Aug 1998	A
5797939	Yoon	Aug 1998	A
5797941	Schulze et al.	Aug 1998	A
5803903	Athas et al.	Sep 1998	A
5808665	Green	Sep 1998	A
5810806	Ritchart et al.	Sep 1998	A
5810849	Kontos	Sep 1998	A
5810865	Koscher et al.	Sep 1998	A
5810876	Kelleher	Sep 1998	A
5810877	Roth et al.	Sep 1998	A
5813976	Filipi et al.	Sep 1998	A
5814058	Carlson et al.	Sep 1998	A
5817061	Goodwin et al.	Oct 1998	A
5817107	Schaller	Oct 1998	A
5817119	Klieman et al.	Oct 1998	A
5819736	Avny et al.	Oct 1998	A
5824071	Nelson et al.	Oct 1998	A
5827281	Levin	Oct 1998	A
5827299	Thomason et al.	Oct 1998	A
5830231	Geiges, Jr.	Nov 1998	A
5833700	Fogelberg et al.	Nov 1998	A
5833703	Manushakian	Nov 1998	A
5843017	Yoon	Dec 1998	A
5843121	Yoon	Dec 1998	A
5849022	Sakashita et al.	Dec 1998	A
5853374	Hart et al.	Dec 1998	A
5855585	Kontos	Jan 1999	A
5860913	Yamaya et al.	Jan 1999	A
5860995	Berkelaar	Jan 1999	A
5868762	Cragg et al.	Feb 1999	A
5876411	Kontos	Mar 1999	A
5882331	Sasaki	Mar 1999	A
5882344	Stouder, Jr.	Mar 1999	A
5893846	Bales et al.	Apr 1999	A
5893874	Bourque et al.	Apr 1999	A
5893875	O'Connor et al.	Apr 1999	A
5899919	Eubanks, Jr. et al.	May 1999	A
5902254	Magram	May 1999	A
5904702	Ek et al.	May 1999	A
5908420	Parins et al.	Jun 1999	A
5911737	Lee et al.	Jun 1999	A
5916147	Boury	Jun 1999	A
5921993	Yoon	Jul 1999	A
5921997	Fogelberg et al.	Jul 1999	A
5922008	Gimpelson	Jul 1999	A
5925052	Simmons	Jul 1999	A
5928255	Meade et al.	Jul 1999	A
5928266	Kontos	Jul 1999	A
5936536	Morris	Aug 1999	A
5944718	Austin et al.	Aug 1999	A
5951549	Richardson et al.	Sep 1999	A
5954720	Wilson et al.	Sep 1999	A
5954731	Yoon	Sep 1999	A
5957943	Vaitekunas	Sep 1999	A
5957953	DiPoto et al.	Sep 1999	A
5971995	Rousseau	Oct 1999	A
5976074	Moriyama	Nov 1999	A
5976075	Beane et al.	Nov 1999	A
5976130	McBrayer et al.	Nov 1999	A
5976131	Guglielmi et al.	Nov 1999	A
5980539	Kontos	Nov 1999	A
5980556	Giordano et al.	Nov 1999	A
5984938	Yoon	Nov 1999	A
5984939	Yoon	Nov 1999	A
5989182	Hori et al.	Nov 1999	A
5993447	Blewett et al.	Nov 1999	A
5997555	Kontos	Dec 1999	A
6001120	Levin	Dec 1999	A
6004269	Crowley et al.	Dec 1999	A
6004330	Middleman et al.	Dec 1999	A
6007566	Wenstrom, Jr.	Dec 1999	A
6010515	Swain et al.	Jan 2000	A
6012494	Balazs	Jan 2000	A
6017356	Frederick et al.	Jan 2000	A
6019770	Christoudias	Feb 2000	A
6024708	Bales et al.	Feb 2000	A
6024747	Kontos	Feb 2000	A
6027522	Palmer	Feb 2000	A
6030365	Laufer	Feb 2000	A
6030634	Wu et al.	Feb 2000	A
6033399	Gines	Mar 2000	A
6036685	Mueller	Mar 2000	A
6053927	Hamas	Apr 2000	A
6066160	Colvin et al.	May 2000	A
6068603	Suzuki	May 2000	A
6068629	Haissaguerre et al.	May 2000	A
6071233	Ishikawa et al.	Jun 2000	A
6074408	Freeman	Jun 2000	A
6086530	Mack	Jul 2000	A
6090108	McBrayer et al.	Jul 2000	A
6096046	Weiss	Aug 2000	A
6102926	Tartaglia et al.	Aug 2000	A
6106473	Violante et al.	Aug 2000	A
6109852	Shahinpoor et al.	Aug 2000	A
6110154	Shimomura et al.	Aug 2000	A
6110183	Cope	Aug 2000	A
6113593	Tu et al.	Sep 2000	A
6117144	Nobles et al.	Sep 2000	A
6117158	Measamer et al.	Sep 2000	A
6139555	Hart et al.	Oct 2000	A
6146391	Cigaina	Nov 2000	A
6148222	Ramsey, III	Nov 2000	A
6149653	Deslauriers	Nov 2000	A
6149662	Pugliesi et al.	Nov 2000	A
6159200	Verdura et al.	Dec 2000	A
6165184	Verdura et al.	Dec 2000	A
6168570	Ferrera	Jan 2001	B1
6168605	Measamer et al.	Jan 2001	B1
6170130	Hamilton et al.	Jan 2001	B1
6179776	Adams et al.	Jan 2001	B1
6179837	Hooven	Jan 2001	B1
6183420	Douk et al.	Feb 2001	B1
6190353	Makower et al.	Feb 2001	B1
6190384	Ouchi	Feb 2001	B1
6190399	Palmer et al.	Feb 2001	B1
6203533	Ouchi	Mar 2001	B1
6206872	Lafond et al.	Mar 2001	B1
6206877	Kese et al.	Mar 2001	B1
6214007	Anderson	Apr 2001	B1
6228096	Marchand	May 2001	B1
6234958	Snoke et al.	May 2001	B1
6245079	Nobles et al.	Jun 2001	B1
6246914	de la Rama et al.	Jun 2001	B1
6258064	Smith et al.	Jul 2001	B1
6261242	Roberts et al.	Jul 2001	B1
6264664	Avellanet	Jul 2001	B1
6270497	Sekino et al.	Aug 2001	B1
6270505	Yoshida et al.	Aug 2001	B1
6277136	Bonutti	Aug 2001	B1
6283963	Regula	Sep 2001	B1
6293909	Chu et al.	Sep 2001	B1
6293952	Brosens et al.	Sep 2001	B1
6296630	Altman et al.	Oct 2001	B1
6322578	Houle et al.	Nov 2001	B1
6326177	Schoenbach et al.	Dec 2001	B1
6328730	Harkrider, Jr.	Dec 2001	B1
6350267	Stefanchik	Feb 2002	B1
6350278	Lenker et al.	Feb 2002	B1
6352503	Matsui et al.	Mar 2002	B1
6352543	Cole	Mar 2002	B1
6355035	Manushakian	Mar 2002	B1
6361534	Chen et al.	Mar 2002	B1
6371956	Wilson et al.	Apr 2002	B1
6379366	Fleischman et al.	Apr 2002	B1
6383195	Richard	May 2002	B1
6383197	Conlon et al.	May 2002	B1
6391029	Hooven et al.	May 2002	B1
6402735	Langevin	Jun 2002	B1
6406440	Stefanchik	Jun 2002	B1
6409733	Conlon et al.	Jun 2002	B1
6427089	Knowlton	Jul 2002	B1
6431500	Jacobs et al.	Aug 2002	B1
6443970	Schulze et al.	Sep 2002	B1
6443988	Felt et al.	Sep 2002	B2
6447511	Slater	Sep 2002	B1
6447523	Middleman et al.	Sep 2002	B1
6454783	Piskun	Sep 2002	B1
6454785	De Hoyos Garza	Sep 2002	B2
6458076	Pruitt	Oct 2002	B1
6464701	Hooven et al.	Oct 2002	B1
6464702	Schulze et al.	Oct 2002	B2
6475104	Lutz et al.	Nov 2002	B1
6485411	Konstorum et al.	Nov 2002	B1
6489745	Koreis	Dec 2002	B1
6491626	Stone et al.	Dec 2002	B1
6491627	Komi	Dec 2002	B1
6491691	Morley et al.	Dec 2002	B1
6493590	Wessman et al.	Dec 2002	B1
6494893	Dubrul et al.	Dec 2002	B2
6500176	Truckai et al.	Dec 2002	B1
6503192	Ouchi	Jan 2003	B1
6506190	Walshe	Jan 2003	B1
6508827	Manhes	Jan 2003	B1
6520954	Ouchi	Feb 2003	B2
6543456	Freeman	Apr 2003	B1
6551270	Bimbo et al.	Apr 2003	B1
6554829	Schulze et al.	Apr 2003	B2
6558384	Mayenberger	May 2003	B2
6562035	Levin	May 2003	B1
6562052	Nobles et al.	May 2003	B2
6569159	Edwards et al.	May 2003	B1
6572629	Kalloo et al.	Jun 2003	B2
6572635	Bonutti	Jun 2003	B1
6575988	Rousseau	Jun 2003	B2
6579311	Makower	Jun 2003	B1
6585642	Christopher	Jul 2003	B2
6585717	Wittenberger et al.	Jul 2003	B1
6592559	Pakter et al.	Jul 2003	B1
6592603	Lasner	Jul 2003	B2
6602262	Griego et al.	Aug 2003	B2
6605105	Cuschieri et al.	Aug 2003	B1
6610072	Christy et al.	Aug 2003	B1
6610074	Santilli	Aug 2003	B2
6620193	Lau et al.	Sep 2003	B1
6623448	Slater	Sep 2003	B2
6626919	Swanstrom	Sep 2003	B1
6632229	Yamanouchi	Oct 2003	B1
6638286	Burbank et al.	Oct 2003	B1
6652521	Schulze	Nov 2003	B2
6652551	Heiss	Nov 2003	B1
6656194	Gannoe et al.	Dec 2003	B1
6663641	Kovac et al.	Dec 2003	B1
6666854	Lange	Dec 2003	B1
6672338	Esashi et al.	Jan 2004	B1
6673058	Snow	Jan 2004	B2
6673087	Chang et al.	Jan 2004	B1
6679882	Kornerup	Jan 2004	B1
6685628	Vu	Feb 2004	B2
6685724	Haluck	Feb 2004	B1
6692445	Roberts et al.	Feb 2004	B2
6692462	Mackenzie et al.	Feb 2004	B2
6699180	Kobayashi	Mar 2004	B2
6699256	Logan et al.	Mar 2004	B1
6699263	Cope	Mar 2004	B2
6706018	Westlund et al.	Mar 2004	B2
6708066	Herbst et al.	Mar 2004	B2
6709445	Boebel et al.	Mar 2004	B2
6716226	Sixto, Jr. et al.	Apr 2004	B2
6736822	McClellan et al.	May 2004	B2
6740030	Martone et al.	May 2004	B2
6743240	Smith et al.	Jun 2004	B2
6749560	Konstorum et al.	Jun 2004	B1
6749609	Lunsford et al.	Jun 2004	B1
6752768	Burdorff et al.	Jun 2004	B2
6752811	Chu et al.	Jun 2004	B2
6752822	Jespersen	Jun 2004	B2
6761685	Adams et al.	Jul 2004	B2
6761718	Madsen	Jul 2004	B2
6773434	Ciarrocca	Aug 2004	B2
6780151	Grabover et al.	Aug 2004	B2
6780352	Jacobson	Aug 2004	B2
6783491	Saadat et al.	Aug 2004	B2
6786864	Matsuura et al.	Sep 2004	B2
6790173	Saadat et al.	Sep 2004	B2
6795728	Chornenky et al.	Sep 2004	B2
6800056	Tartaglia et al.	Oct 2004	B2
6808491	Kortenbach et al.	Oct 2004	B2
6824548	Smith et al.	Nov 2004	B2
6837847	Ewers et al.	Jan 2005	B2
6843794	Sixto, Jr. et al.	Jan 2005	B2
6861250	Cole et al.	Mar 2005	B1
6866627	Nozue	Mar 2005	B2
6878106	Herrmann	Apr 2005	B1
6878110	Yang et al.	Apr 2005	B2
6881216	Di Caprio et al.	Apr 2005	B2
6884213	Raz et al.	Apr 2005	B2
6887255	Shimm	May 2005	B2
6889089	Behl et al.	May 2005	B2
6896683	Gadberry et al.	May 2005	B1
6896692	Ginn et al.	May 2005	B2
6908427	Fleener et al.	Jun 2005	B2
6908476	Jud et al.	Jun 2005	B2
6916284	Moriyama	Jul 2005	B2
6918871	Schulze	Jul 2005	B2
6926725	Cooke et al.	Aug 2005	B2
6932810	Ryan	Aug 2005	B2
6932824	Roop et al.	Aug 2005	B1
6932827	Cole	Aug 2005	B2
6939327	Hall et al.	Sep 2005	B2
6942613	Ewers et al.	Sep 2005	B2
6945472	Wuttke et al.	Sep 2005	B2
6945979	Kortenbach et al.	Sep 2005	B2
6958035	Friedman et al.	Oct 2005	B2
6960162	Saadat et al.	Nov 2005	B2
6960163	Ewers et al.	Nov 2005	B2
6962587	Johnson et al.	Nov 2005	B2
6964662	Kidooka	Nov 2005	B2
6966909	Marshall et al.	Nov 2005	B2
6966919	Sixto, Jr. et al.	Nov 2005	B2
6967462	Landis	Nov 2005	B1
6971988	Orban, III	Dec 2005	B2
6972017	Smith et al.	Dec 2005	B2
6974411	Belson	Dec 2005	B2
6976992	Sachatello et al.	Dec 2005	B2
6984203	Tartaglia et al.	Jan 2006	B2
6984205	Gazdzinski	Jan 2006	B2
6986774	Middleman et al.	Jan 2006	B2
6988987	Ishikawa et al.	Jan 2006	B2
6989028	Lashinski et al.	Jan 2006	B2
6991627	Madhani et al.	Jan 2006	B2
6991631	Woloszko et al.	Jan 2006	B2
6994708	Manzo	Feb 2006	B2
6997931	Sauer et al.	Feb 2006	B2
7000818	Shelton, IV et al.	Feb 2006	B2
7001341	Gellman et al.	Feb 2006	B2
7008375	Weisel	Mar 2006	B2
7009634	Iddan et al.	Mar 2006	B2
7010340	Scarantino et al.	Mar 2006	B2
7020531	Colliou et al.	Mar 2006	B1
7025580	Heagy et al.	Apr 2006	B2
7029435	Nakao	Apr 2006	B2
7029438	Morin et al.	Apr 2006	B2
7029450	Gellman	Apr 2006	B2
7035680	Partridge et al.	Apr 2006	B2
7037290	Gardeski et al.	May 2006	B2
7041052	Saadat et al.	May 2006	B2
7052489	Griego et al.	May 2006	B2
7060024	Long et al.	Jun 2006	B2
7060025	Long et al.	Jun 2006	B2
7063697	Slater	Jun 2006	B2
7063715	Onuki et al.	Jun 2006	B2
7066879	Fowler et al.	Jun 2006	B2
7066936	Ryan	Jun 2006	B2
7070602	Smith et al.	Jul 2006	B2
7076305	Imran et al.	Jul 2006	B2
7083618	Couture et al.	Aug 2006	B2
7083620	Jahns et al.	Aug 2006	B2
7083629	Weller et al.	Aug 2006	B2
7083635	Ginn	Aug 2006	B2
7087071	Nicholas et al.	Aug 2006	B2
7090673	Dycus et al.	Aug 2006	B2
7090685	Kortenbach et al.	Aug 2006	B2
7093518	Gmeilbauer	Aug 2006	B2
7101371	Dycus et al.	Sep 2006	B2
7101372	Dycus et al.	Sep 2006	B2
7101373	Dycus et al.	Sep 2006	B2
7105000	McBrayer	Sep 2006	B2
7105005	Blake	Sep 2006	B2
7108703	Danitz et al.	Sep 2006	B2
7112208	Morris et al.	Sep 2006	B2
7115092	Park et al.	Oct 2006	B2
7117703	Kato et al.	Oct 2006	B2
7118531	Krill	Oct 2006	B2
7118578	West, Jr. et al.	Oct 2006	B2
7118587	Dycus et al.	Oct 2006	B2
7128708	Saadat et al.	Oct 2006	B2
RE39415	Bales et al.	Nov 2006	E
7131978	Sancoff et al.	Nov 2006	B2
7131979	DiCarlo et al.	Nov 2006	B2
7131980	Field et al.	Nov 2006	B1
7137980	Buysse et al.	Nov 2006	B2
7137981	Long	Nov 2006	B2
7146984	Stack et al.	Dec 2006	B2
7147650	Lee	Dec 2006	B2
7150097	Sremcich et al.	Dec 2006	B2
7153321	Andrews	Dec 2006	B2
7163525	Franer	Jan 2007	B2
7172714	Jacobson	Feb 2007	B2
7179254	Pendekanti et al.	Feb 2007	B2
7188627	Nelson et al.	Mar 2007	B2
7195612	Van Sloten et al.	Mar 2007	B2
7195631	Dumbauld	Mar 2007	B2
7204820	Akahoshi	Apr 2007	B2
7208005	Frecker et al.	Apr 2007	B2
7211092	Hughett	May 2007	B2
7220227	Sasaki et al.	May 2007	B2
7223272	Francere et al.	May 2007	B2
7232414	Gonzalez	Jun 2007	B2
7232445	Kortenbach et al.	Jun 2007	B2
7241290	Doyle et al.	Jul 2007	B2
7244228	Lubowski	Jul 2007	B2
7250027	Barry	Jul 2007	B2
7252660	Kunz	Aug 2007	B2
7255675	Gertner et al.	Aug 2007	B2
7270663	Nakao	Sep 2007	B2
7294139	Gengler	Nov 2007	B1
7301250	Cassel	Nov 2007	B2
7306597	Manzo	Dec 2007	B2
7308828	Hashimoto	Dec 2007	B2
7318802	Suzuki et al.	Jan 2008	B2
7320695	Carroll	Jan 2008	B2
7322934	Miyake et al.	Jan 2008	B2
7323006	Andreas et al.	Jan 2008	B2
7329256	Johnson et al.	Feb 2008	B2
7329257	Kanehira et al.	Feb 2008	B2
7329383	Stinson	Feb 2008	B2
7344536	Lunsford et al.	Mar 2008	B1
7352387	Yamamoto	Apr 2008	B2
7364582	Lee	Apr 2008	B2
7371215	Colliou et al.	May 2008	B2
7381216	Buzzard et al.	Jun 2008	B2
7393322	Wenchell	Jul 2008	B2
7402162	Ouchi	Jul 2008	B2
7404791	Linares et al.	Jul 2008	B2
7413563	Corcoran et al.	Aug 2008	B2
7416554	Lam et al.	Aug 2008	B2
7422590	Kupferschmid et al.	Sep 2008	B2
7435257	Lashinski et al.	Oct 2008	B2
7452327	Durgin et al.	Nov 2008	B2
7455208	Wales et al.	Nov 2008	B2
7468066	Vargas et al.	Dec 2008	B2
7488295	Burbank et al.	Feb 2009	B2
7497867	Lasner et al.	Mar 2009	B2
7507200	Okada	Mar 2009	B2
7524281	Chu et al.	Apr 2009	B2
7524302	Tower	Apr 2009	B2
7534228	Williams	May 2009	B2
7540872	Schechter et al.	Jun 2009	B2
7544203	Chin et al.	Jun 2009	B2
7548040	Lee et al.	Jun 2009	B2
7549564	Boudreaux	Jun 2009	B2
7553278	Kucklick	Jun 2009	B2
7553298	Hunt et al.	Jun 2009	B2
7559887	Dannan	Jul 2009	B2
7559916	Smith et al.	Jul 2009	B2
7560006	Rakos et al.	Jul 2009	B2
7561916	Hunt et al.	Jul 2009	B2
7566334	Christian et al.	Jul 2009	B2
7575144	Ortiz et al.	Aug 2009	B2
7575548	Takemoto et al.	Aug 2009	B2
7579550	Dayton et al.	Aug 2009	B2
7582096	Gellman et al.	Sep 2009	B2
7588177	Racenet	Sep 2009	B2
7588557	Nakao	Sep 2009	B2
7618398	Holman et al.	Nov 2009	B2
7632250	Smith et al.	Dec 2009	B2
7635373	Ortiz	Dec 2009	B2
7637903	Lentz et al.	Dec 2009	B2
7651483	Byrum et al.	Jan 2010	B2
7651509	Bojarski et al.	Jan 2010	B2
7654431	Hueil et al.	Feb 2010	B2
7662089	Okada et al.	Feb 2010	B2
7666180	Holsten et al.	Feb 2010	B2
7674259	Shadduck	Mar 2010	B2
7713189	Hanke	May 2010	B2
7713270	Suzuki	May 2010	B2
7736374	Vaughan et al.	Jun 2010	B2
7744615	Couture	Jun 2010	B2
7758577	Nobis et al.	Jul 2010	B2
7762998	Birk et al.	Jul 2010	B2
7771416	Spivey et al.	Aug 2010	B2
7780683	Roue et al.	Aug 2010	B2
7780691	Stefanchik	Aug 2010	B2
7794409	Damarati	Sep 2010	B2
7794475	Hess et al.	Sep 2010	B2
7828186	Wales	Nov 2010	B2
7837615	Le et al.	Nov 2010	B2
7846171	Kullas et al.	Dec 2010	B2
7850660	Uth et al.	Dec 2010	B2
7857183	Shelton, IV	Dec 2010	B2
7862546	Conlon et al.	Jan 2011	B2
7867216	Wahr et al.	Jan 2011	B2
7892220	Faller et al.	Feb 2011	B2
7896887	Rimbaugh et al.	Mar 2011	B2
7909809	Scopton et al.	Mar 2011	B2
7914513	Voorhees, Jr.	Mar 2011	B2
7918869	Saadat et al.	Apr 2011	B2
7931624	Smith et al.	Apr 2011	B2
7945332	Schechter	May 2011	B2
7947000	Vargas et al.	May 2011	B2
7955298	Carroll et al.	Jun 2011	B2
7963975	Criscuolo	Jun 2011	B2
7988685	Ziaie et al.	Aug 2011	B2
8075587	Ginn	Dec 2011	B2
20010049497	Kalloo et al.	Dec 2001	A1
20020022771	Diokno et al.	Feb 2002	A1
20020022857	Goldsteen et al.	Feb 2002	A1
20020023353	Ting-Kung	Feb 2002	A1
20020029055	Bonutti	Mar 2002	A1
20020032441	Ingle et al.	Mar 2002	A1
20020042562	Meron et al.	Apr 2002	A1
20020049439	Mulier et al.	Apr 2002	A1
20020068945	Sixto, Jr. et al.	Jun 2002	A1
20020078967	Sixto, Jr. et al.	Jun 2002	A1
20020082516	Stefanchik	Jun 2002	A1
20020091391	Cole et al.	Jul 2002	A1
20020095164	Andreas et al.	Jul 2002	A1
20020107530	Sauer et al.	Aug 2002	A1
20020133115	Gordon et al.	Sep 2002	A1
20020137997	Mastrototaro et al.	Sep 2002	A1
20020138086	Sixto, Jr. et al.	Sep 2002	A1
20020147456	Diduch et al.	Oct 2002	A1
20020183591	Matsuura et al.	Dec 2002	A1
20030023255	Miles et al.	Jan 2003	A1
20030036679	Kortenbach et al.	Feb 2003	A1
20030069602	Jacobs et al.	Apr 2003	A1
20030083681	Moutafis et al.	May 2003	A1
20030114732	Webler et al.	Jun 2003	A1
20030120257	Houston et al.	Jun 2003	A1
20030124009	Ravi et al.	Jul 2003	A1
20030130564	Martone et al.	Jul 2003	A1
20030130656	Levin	Jul 2003	A1
20030158521	Ameri	Aug 2003	A1
20030167062	Gambale et al.	Sep 2003	A1
20030171651	Page et al.	Sep 2003	A1
20030176880	Long et al.	Sep 2003	A1
20030191497	Cope	Oct 2003	A1
20030195565	Bonutti	Oct 2003	A1
20030216611	Vu	Nov 2003	A1
20030216615	Ouchi	Nov 2003	A1
20030220545	Ouchi	Nov 2003	A1
20030225312	Suzuki et al.	Dec 2003	A1
20030225332	Okada et al.	Dec 2003	A1
20030229269	Humphrey	Dec 2003	A1
20030229371	Whitworth	Dec 2003	A1
20030236549	Bonadio et al.	Dec 2003	A1
20040002683	Nicholson et al.	Jan 2004	A1
20040002735	Lizardi et al.	Jan 2004	A1
20040034369	Sauer et al.	Feb 2004	A1
20040098007	Heiss	May 2004	A1
20040101456	Kuroshima et al.	May 2004	A1
20040116948	Sixto, Jr. et al.	Jun 2004	A1
20040127940	Ginn et al.	Jul 2004	A1
20040133077	Obenchain et al.	Jul 2004	A1
20040133089	Kilcoyne et al.	Jul 2004	A1
20040136779	Bhaskar	Jul 2004	A1
20040138525	Saadat et al.	Jul 2004	A1
20040138529	Wiltshire et al.	Jul 2004	A1
20040138587	Lyons, IV	Jul 2004	A1
20040161451	Pierce et al.	Aug 2004	A1
20040186350	Brenneman et al.	Sep 2004	A1
20040193009	Jaffe et al.	Sep 2004	A1
20040193146	Lee et al.	Sep 2004	A1
20040193186	Kortenbach et al.	Sep 2004	A1
20040193188	Francese	Sep 2004	A1
20040193189	Kortenbach et al.	Sep 2004	A1
20040193200	Dworschak et al.	Sep 2004	A1
20040199052	Banik et al.	Oct 2004	A1
20040210245	Erickson et al.	Oct 2004	A1
20040215058	Zirps et al.	Oct 2004	A1
20040225183	Michlitsch et al.	Nov 2004	A1
20040225186	Horne, Jr. et al.	Nov 2004	A1
20040230095	Stefanchik et al.	Nov 2004	A1
20040230096	Stefanchik et al.	Nov 2004	A1
20040230097	Stefanchik et al.	Nov 2004	A1
20040230161	Zeiner	Nov 2004	A1
20040249246	Campos	Dec 2004	A1
20040249367	Saadat et al.	Dec 2004	A1
20040249394	Morris et al.	Dec 2004	A1
20040249443	Shanley et al.	Dec 2004	A1
20050004515	Hart et al.	Jan 2005	A1
20050033265	Engel et al.	Feb 2005	A1
20050033277	Clague et al.	Feb 2005	A1
20050033319	Gambale et al.	Feb 2005	A1
20050033333	Smith et al.	Feb 2005	A1
20050043690	Todd	Feb 2005	A1
20050049616	Rivera et al.	Mar 2005	A1
20050065397	Saadat et al.	Mar 2005	A1
20050065517	Chin	Mar 2005	A1
20050070754	Nobis et al.	Mar 2005	A1
20050070763	Nobis et al.	Mar 2005	A1
20050070764	Nobis et al.	Mar 2005	A1
20050080413	Canady	Apr 2005	A1
20050085693	Belson et al.	Apr 2005	A1
20050085832	Sancoff et al.	Apr 2005	A1
20050090837	Sixto, Jr. et al.	Apr 2005	A1
20050090838	Sixto, Jr. et al.	Apr 2005	A1
20050101837	Kalloo et al.	May 2005	A1
20050101838	Camillocci et al.	May 2005	A1
20050107663	Saadat et al.	May 2005	A1
20050107664	Kalloo et al.	May 2005	A1
20050110881	Glukhovsky et al.	May 2005	A1
20050113847	Gadberry et al.	May 2005	A1
20050119613	Moenning et al.	Jun 2005	A1
20050124855	Jaffe et al.	Jun 2005	A1
20050125010	Smith et al.	Jun 2005	A1
20050131279	Boulais et al.	Jun 2005	A1
20050131457	Douglas et al.	Jun 2005	A1
20050137454	Saadat et al.	Jun 2005	A1
20050143647	Minai et al.	Jun 2005	A1
20050143690	High	Jun 2005	A1
20050143774	Polo	Jun 2005	A1
20050143803	Watson et al.	Jun 2005	A1
20050149087	Ahlberg et al.	Jul 2005	A1
20050149096	Hilal et al.	Jul 2005	A1
20050159648	Freed	Jul 2005	A1
20050165272	Okada et al.	Jul 2005	A1
20050165378	Heinrich et al.	Jul 2005	A1
20050165411	Orban, III	Jul 2005	A1
20050165429	Douglas et al.	Jul 2005	A1
20050182429	Yamanouchi	Aug 2005	A1
20050192478	Williams et al.	Sep 2005	A1
20050192598	Johnson et al.	Sep 2005	A1
20050192602	Manzo	Sep 2005	A1
20050192654	Chanduszko et al.	Sep 2005	A1
20050209624	Vijay	Sep 2005	A1
20050215858	Vail, III	Sep 2005	A1
20050216050	Sepetka et al.	Sep 2005	A1
20050228406	Bose	Oct 2005	A1
20050234297	Devierre et al.	Oct 2005	A1
20050250983	Tremaglio et al.	Nov 2005	A1
20050250990	Le et al.	Nov 2005	A1
20050250993	Jaeger	Nov 2005	A1
20050251166	Vaughan et al.	Nov 2005	A1
20050251176	Swanstrom et al.	Nov 2005	A1
20050261674	Nobis et al.	Nov 2005	A1
20050267492	Poncet et al.	Dec 2005	A1
20050272975	McWeeney et al.	Dec 2005	A1
20050272977	Saadat et al.	Dec 2005	A1
20050273084	Hinman et al.	Dec 2005	A1
20050277945	Saadat et al.	Dec 2005	A1
20050277951	Smith et al.	Dec 2005	A1
20050277952	Arp et al.	Dec 2005	A1
20050277954	Smith et al.	Dec 2005	A1
20050277955	Palmer et al.	Dec 2005	A1
20050277956	Francese et al.	Dec 2005	A1
20050277957	Kuhns et al.	Dec 2005	A1
20050283118	Uth et al.	Dec 2005	A1
20050283119	Uth et al.	Dec 2005	A1
20050288555	Binmoeller	Dec 2005	A1
20060004406	Wehrstein et al.	Jan 2006	A1
20060004409	Nobis et al.	Jan 2006	A1
20060004410	Nobis et al.	Jan 2006	A1
20060015009	Jaffe et al.	Jan 2006	A1
20060020167	Sitzmann	Jan 2006	A1
20060020247	Kagan et al.	Jan 2006	A1
20060025654	Suzuki et al.	Feb 2006	A1
20060025781	Young et al.	Feb 2006	A1
20060025812	Shelton, IV	Feb 2006	A1
20060025819	Nobis et al.	Feb 2006	A1
20060036267	Saadat et al.	Feb 2006	A1
20060041188	Dirusso et al.	Feb 2006	A1
20060058582	Maahs et al.	Mar 2006	A1
20060058776	Bilsbury	Mar 2006	A1
20060069396	Meade et al.	Mar 2006	A1
20060069424	Acosta et al.	Mar 2006	A1
20060069425	Hillis et al.	Mar 2006	A1
20060074413	Behzadian	Apr 2006	A1
20060079890	Guerra	Apr 2006	A1
20060089528	Tartaglia et al.	Apr 2006	A1
20060095031	Ormsby	May 2006	A1
20060095060	Mayenberger et al.	May 2006	A1
20060100687	Fahey et al.	May 2006	A1
20060106423	Weisel et al.	May 2006	A1
20060111209	Hinman et al.	May 2006	A1
20060111210	Hinman et al.	May 2006	A1
20060111704	Brenneman et al.	May 2006	A1
20060129166	Lavelle	Jun 2006	A1
20060135962	Kick et al.	Jun 2006	A1
20060135971	Swanstrom et al.	Jun 2006	A1
20060135984	Kramer et al.	Jun 2006	A1
20060142644	Mulac et al.	Jun 2006	A1
20060142652	Keenan	Jun 2006	A1
20060142790	Gertner	Jun 2006	A1
20060142798	Holman et al.	Jun 2006	A1
20060149131	Or	Jul 2006	A1
20060149132	Iddan	Jul 2006	A1
20060149135	Paz	Jul 2006	A1
20060161190	Gadberry et al.	Jul 2006	A1
20060167416	Mathis et al.	Jul 2006	A1
20060167482	Swain et al.	Jul 2006	A1
20060178560	Saadat et al.	Aug 2006	A1
20060183975	Saadat et al.	Aug 2006	A1
20060184161	Maahs et al.	Aug 2006	A1
20060189844	Tien	Aug 2006	A1
20060189845	Maahs et al.	Aug 2006	A1
20060190027	Downey	Aug 2006	A1
20060195084	Slater	Aug 2006	A1
20060200005	Bjork et al.	Sep 2006	A1
20060200169	Sniffin	Sep 2006	A1
20060200170	Aranyi	Sep 2006	A1
20060200199	Bonutti et al.	Sep 2006	A1
20060217665	Prosek	Sep 2006	A1
20060217697	Lau et al.	Sep 2006	A1
20060217742	Messerly et al.	Sep 2006	A1
20060217743	Messerly et al.	Sep 2006	A1
20060229639	Whitfield	Oct 2006	A1
20060229640	Whitfield	Oct 2006	A1
20060237022	Chen et al.	Oct 2006	A1
20060237023	Cox et al.	Oct 2006	A1
20060241570	Wilk	Oct 2006	A1
20060247576	Poncet	Nov 2006	A1
20060247673	Voegele et al.	Nov 2006	A1
20060253004	Frisch et al.	Nov 2006	A1
20060253039	McKenna et al.	Nov 2006	A1
20060258907	Stefanchik et al.	Nov 2006	A1
20060258908	Stefanchik et al.	Nov 2006	A1
20060258910	Stefanchik et al.	Nov 2006	A1
20060258954	Timberlake et al.	Nov 2006	A1
20060258955	Hoffman et al.	Nov 2006	A1
20060259010	Stefanchik et al.	Nov 2006	A1
20060264752	Rubinsky et al.	Nov 2006	A1
20060264904	Kerby et al.	Nov 2006	A1
20060264930	Nishimura	Nov 2006	A1
20060270902	Igarashi et al.	Nov 2006	A1
20060271102	Bosshard et al.	Nov 2006	A1
20060276835	Uchida	Dec 2006	A1
20060281970	Stokes et al.	Dec 2006	A1
20060282106	Cole et al.	Dec 2006	A1
20060285732	Horn et al.	Dec 2006	A1
20060287644	Inganas et al.	Dec 2006	A1
20060287666	Saadat et al.	Dec 2006	A1
20060293626	Byrum et al.	Dec 2006	A1
20070002135	Glukhovsky	Jan 2007	A1
20070005019	Okishige	Jan 2007	A1
20070010801	Chen et al.	Jan 2007	A1
20070015965	Cox et al.	Jan 2007	A1
20070016225	Nakao	Jan 2007	A1
20070032700	Fowler et al.	Feb 2007	A1
20070032701	Fowler et al.	Feb 2007	A1
20070043261	Watanabe et al.	Feb 2007	A1
20070043345	Davalos et al.	Feb 2007	A1
20070049800	Boulais	Mar 2007	A1
20070049902	Griffin et al.	Mar 2007	A1
20070051375	Milliman	Mar 2007	A1
20070060880	Gregorich et al.	Mar 2007	A1
20070067017	Trapp	Mar 2007	A1
20070073102	Matsuno et al.	Mar 2007	A1
20070073269	Becker	Mar 2007	A1
20070079924	Saadat et al.	Apr 2007	A1
20070088370	Kahle et al.	Apr 2007	A1
20070100375	Mikkaichi et al.	May 2007	A1
20070100376	Mikkaichi et al.	May 2007	A1
20070106118	Moriyama	May 2007	A1
20070112251	Nakhuda	May 2007	A1
20070112331	Weber et al.	May 2007	A1
20070112342	Pearson et al.	May 2007	A1
20070112383	Conlon et al.	May 2007	A1
20070112384	Conlon et al.	May 2007	A1
20070112385	Conlon	May 2007	A1
20070112417	Shanley et al.	May 2007	A1
20070112425	Schaller et al.	May 2007	A1
20070118115	Artale et al.	May 2007	A1
20070123840	Cox	May 2007	A1
20070129605	Schaaf	Jun 2007	A1
20070129719	Kendale et al.	Jun 2007	A1
20070129760	Demarais et al.	Jun 2007	A1
20070135709	Rioux et al.	Jun 2007	A1
20070135803	Belson	Jun 2007	A1
20070142706	Matsui et al.	Jun 2007	A1
20070142780	Van Lue	Jun 2007	A1
20070154460	Kraft et al.	Jul 2007	A1
20070156028	Van Lue et al.	Jul 2007	A1
20070156127	Rioux et al.	Jul 2007	A1
20070161855	Mikkaichi et al.	Jul 2007	A1
20070162101	Burgermeister et al.	Jul 2007	A1
20070173691	Yokoi et al.	Jul 2007	A1
20070173869	Gannoe et al.	Jul 2007	A1
20070173870	Zacharias	Jul 2007	A2
20070173872	Neuenfeldt	Jul 2007	A1
20070179525	Frecker et al.	Aug 2007	A1
20070179530	Tieu et al.	Aug 2007	A1
20070197865	Miyake et al.	Aug 2007	A1
20070198057	Gelbart et al.	Aug 2007	A1
20070203487	Sugita	Aug 2007	A1
20070208336	Kim et al.	Sep 2007	A1
20070208364	Smith et al.	Sep 2007	A1
20070213754	Mikkaichi et al.	Sep 2007	A1
20070225554	Maseda et al.	Sep 2007	A1
20070233040	Macnamara et al.	Oct 2007	A1
20070244358	Lee	Oct 2007	A1
20070250038	Boulais	Oct 2007	A1
20070250057	Nobis et al.	Oct 2007	A1
20070255096	Stefanchik et al.	Nov 2007	A1
20070255100	Barlow et al.	Nov 2007	A1
20070255273	Fernandez et al.	Nov 2007	A1
20070255303	Bakos et al.	Nov 2007	A1
20070255306	Conlon et al.	Nov 2007	A1
20070260112	Rahmani	Nov 2007	A1
20070260117	Zwolinski et al.	Nov 2007	A1
20070260121	Bakos et al.	Nov 2007	A1
20070260273	Cropper et al.	Nov 2007	A1
20070270629	Charles	Nov 2007	A1
20070270889	Conlon et al.	Nov 2007	A1
20070270895	Nobis et al.	Nov 2007	A1
20070270907	Stokes et al.	Nov 2007	A1
20070282371	Lee et al.	Dec 2007	A1
20070293727	Goldfarb et al.	Dec 2007	A1
20070299387	Williams et al.	Dec 2007	A1
20080004650	George	Jan 2008	A1
20080015409	Barlow et al.	Jan 2008	A1
20080015552	Doyle et al.	Jan 2008	A1
20080021416	Arai et al.	Jan 2008	A1
20080022927	Zhang et al.	Jan 2008	A1
20080027387	Grabinsky	Jan 2008	A1
20080033451	Rieber et al.	Feb 2008	A1
20080051629	Sugiyama et al.	Feb 2008	A1
20080051735	Measamer et al.	Feb 2008	A1
20080058586	Karpiel	Mar 2008	A1
20080065169	Colliou et al.	Mar 2008	A1
20080071264	Azure	Mar 2008	A1
20080086172	Martin et al.	Apr 2008	A1
20080097159	Ishiguro	Apr 2008	A1
20080097472	Agmon et al.	Apr 2008	A1
20080097483	Ortiz et al.	Apr 2008	A1
20080103527	Martin et al.	May 2008	A1
20080114384	Chang et al.	May 2008	A1
20080119870	Williams	May 2008	A1
20080119891	Miles et al.	May 2008	A1
20080125796	Graham	May 2008	A1
20080132892	Lunsford et al.	Jun 2008	A1
20080139882	Fujimori	Jun 2008	A1
20080147113	Nobis et al.	Jun 2008	A1
20080171907	Long et al.	Jul 2008	A1
20080177135	Muyari et al.	Jul 2008	A1
20080188868	Weitzner et al.	Aug 2008	A1
20080200755	Bakos	Aug 2008	A1
20080200762	Stokes et al.	Aug 2008	A1
20080200911	Long	Aug 2008	A1
20080200912	Long	Aug 2008	A1
20080200933	Bakos et al.	Aug 2008	A1
20080200934	Fox	Aug 2008	A1
20080208213	Benjamin et al.	Aug 2008	A1
20080221587	Schwartz	Sep 2008	A1
20080221619	Spivey et al.	Sep 2008	A1
20080228213	Blakeney et al.	Sep 2008	A1
20080230972	Ganley	Sep 2008	A1
20080234696	Taylor et al.	Sep 2008	A1
20080243106	Coe et al.	Oct 2008	A1
20080243148	Mikkaichi et al.	Oct 2008	A1
20080243176	Weitzner et al.	Oct 2008	A1
20080249567	Kaplan	Oct 2008	A1
20080262540	Bangera et al.	Oct 2008	A1
20080269782	Stefanchik et al.	Oct 2008	A1
20080269783	Griffith	Oct 2008	A1
20080275474	Martin et al.	Nov 2008	A1
20080275475	Schwemberger et al.	Nov 2008	A1
20080287737	Dejima	Nov 2008	A1
20080287983	Smith et al.	Nov 2008	A1
20080300461	Shaw et al.	Dec 2008	A1
20080300547	Bakos	Dec 2008	A1
20080309758	Karasawa et al.	Dec 2008	A1
20080312496	Zwolinski	Dec 2008	A1
20080312499	Handa et al.	Dec 2008	A1
20080312500	Asada et al.	Dec 2008	A1
20080312506	Spivey et al.	Dec 2008	A1
20080319436	Daniel et al.	Dec 2008	A1
20080319439	Ootsubu	Dec 2008	A1
20090054728	Trusty	Feb 2009	A1
20090062788	Long et al.	Mar 2009	A1
20090062792	Vakharia et al.	Mar 2009	A1
20090062795	Vakharia et al.	Mar 2009	A1
20090069634	Larkin	Mar 2009	A1
20090076499	Azure	Mar 2009	A1
20090078736	Van Lue	Mar 2009	A1
20090082776	Cresina	Mar 2009	A1
20090082779	Nakao	Mar 2009	A1
20090112059	Nobis	Apr 2009	A1
20090112062	Bakos	Apr 2009	A1
20090112063	Bakos et al.	Apr 2009	A1
20090125042	Mouw	May 2009	A1
20090131751	Spivey et al.	May 2009	A1
20090131932	Vakharia et al.	May 2009	A1
20090131933	Ghabrial et al.	May 2009	A1
20090143639	Stark	Jun 2009	A1
20090143649	Rossi	Jun 2009	A1
20090143794	Conlon et al.	Jun 2009	A1
20090143818	Faller et al.	Jun 2009	A1
20090149710	Stefanchik et al.	Jun 2009	A1
20090177031	Surti et al.	Jul 2009	A1
20090177219	Conlon	Jul 2009	A1
20090182332	Long et al.	Jul 2009	A1
20090192344	Bakos et al.	Jul 2009	A1
20090192534	Ortiz et al.	Jul 2009	A1
20090198231	Esser et al.	Aug 2009	A1
20090227828	Swain et al.	Sep 2009	A1
20090248055	Spivey et al.	Oct 2009	A1
20090281559	Swain et al.	Nov 2009	A1
20090287206	Jun	Nov 2009	A1
20090287236	Bakos et al.	Nov 2009	A1
20090292164	Yamatani	Nov 2009	A1
20090299135	Spivey	Dec 2009	A1
20090299143	Conlon et al.	Dec 2009	A1
20090299362	Long et al.	Dec 2009	A1
20090299385	Stefanchik et al.	Dec 2009	A1
20090299406	Swain et al.	Dec 2009	A1
20090299409	Coe et al.	Dec 2009	A1
20090306658	Nobis et al.	Dec 2009	A1
20090306683	Zwolinski et al.	Dec 2009	A1
20090322864	Karasawa et al.	Dec 2009	A1
20090326561	Carroll, II et al.	Dec 2009	A1
20100010294	Conlon et al.	Jan 2010	A1
20100010298	Bakos et al.	Jan 2010	A1
20100010299	Bakos et al.	Jan 2010	A1
20100010303	Bakos	Jan 2010	A1
20100010510	Stefanchik	Jan 2010	A1
20100010511	Harris et al.	Jan 2010	A1
20100023032	Granja Filho	Jan 2010	A1
20100036198	Tacchino et al.	Feb 2010	A1
20100042045	Spivey	Feb 2010	A1
20100048990	Bakos	Feb 2010	A1
20100049223	Granja Filho	Feb 2010	A1
20100056861	Spivey	Mar 2010	A1
20100056862	Bakos	Mar 2010	A1
20100057085	Holcomb et al.	Mar 2010	A1
20100057108	Spivey et al.	Mar 2010	A1
20100063538	Spivey et al.	Mar 2010	A1
20100076451	Zwolinski et al.	Mar 2010	A1
20100081877	Vakharia	Apr 2010	A1
20100087813	Long	Apr 2010	A1
20100113872	Asada et al.	May 2010	A1
20100121362	Clague et al.	May 2010	A1
20100130817	Conlon	May 2010	A1
20100130975	Long	May 2010	A1
20100131005	Conlon	May 2010	A1
20100152539	Ghabrial et al.	Jun 2010	A1
20100152609	Zwolinski et al.	Jun 2010	A1
20100152746	Ceniccola et al.	Jun 2010	A1
20100179510	Fox et al.	Jul 2010	A1
20100179530	Long et al.	Jul 2010	A1
20100191050	Zwolinski	Jul 2010	A1
20100191267	Fox	Jul 2010	A1
20100198005	Fox	Aug 2010	A1
20100198149	Fox	Aug 2010	A1
20100198244	Spivey et al.	Aug 2010	A1
20100198248	Vakharia	Aug 2010	A1
20100249700	Spivey	Sep 2010	A1
20100286791	Goldsmith	Nov 2010	A1
20100298642	Trusty et al.	Nov 2010	A1
20100312056	Galperin et al.	Dec 2010	A1
20100331622	Conlon	Dec 2010	A2
20100331774	Spivey	Dec 2010	A2
20110093009	Fox	Apr 2011	A1
20110098694	Long	Apr 2011	A1
20110098704	Long et al.	Apr 2011	A1
20110105850	Voegele et al.	May 2011	A1
20110112434	Ghabrial et al.	May 2011	A1
20110115891	Trusty	May 2011	A1
20110124964	Nobis	May 2011	A1
20110152609	Trusty et al.	Jun 2011	A1
20110152610	Trusty et al.	Jun 2011	A1
20110152612	Trusty et al.	Jun 2011	A1
20110152858	Long et al.	Jun 2011	A1
20110152859	Long et al.	Jun 2011	A1
20110152878	Trusty et al.	Jun 2011	A1
20110152923	Fox	Jun 2011	A1
20110160514	Long et al.	Jun 2011	A1
20110190659	Long et al.	Aug 2011	A1
20110190764	Long et al.	Aug 2011	A1
20110245619	Holcomb	Oct 2011	A1
20110306971	Long	Dec 2011	A1

Foreign Referenced Citations (151)

Number	Date	Country
666310	Feb 1996	AU
3008120	Sep 1980	DE
4323585	Jan 1995	DE
19713797	Oct 1997	DE
19757056	Aug 2008	DE
102006027873	Oct 2009	DE
0086338	Aug 1983	EP
0286415	Oct 1988	EP
0589454	Mar 1994	EP
0464479	Mar 1995	EP
0529675	Feb 1996	EP
0724863	Jul 1999	EP
0760629	Nov 1999	EP
0818974	Jul 2001	EP
1281356	Feb 2003	EP
0947166	May 2003	EP
0836832	Dec 2003	EP
1402837	Mar 2004	EP
0744918	Apr 2004	EP
0931515	Aug 2004	EP
0941128	Oct 2004	EP
1411843	Oct 2004	EP
1150614	Nov 2004	EP
1477104	Nov 2004	EP
1481642	Dec 2004	EP
1493391	Jan 2005	EP
0848598	Feb 2005	EP
1281360	Mar 2005	EP
1568330	Aug 2005	EP
1452143	Sep 2005	EP
1616527	Jan 2006	EP
1006888	Mar 2006	EP
1629764	Mar 2006	EP
1013229	Jun 2006	EP
1721561	Nov 2006	EP
1153578	Mar 2007	EP
1334696	Mar 2007	EP
1769766	Apr 2007	EP
1836971	Sep 2007	EP
1836980	Sep 2007	EP
1854421	Nov 2007	EP
1857061	Nov 2007	EP
1875876	Jan 2008	EP
1891881	Feb 2008	EP
1902663	Mar 2008	EP
1477106	Jun 2008	EP
1949844	Jul 2008	EP
1518499	Aug 2008	EP
1709918	Oct 2008	EP
1985226	Oct 2008	EP
1994904	Nov 2008	EP
1707130	Dec 2008	EP
0723462	Mar 2009	EP
1769749	Nov 2009	EP
1493397	Sep 2011	EP
2731610	Sep 1996	FR
330629	Jun 1930	GB
2335860	Oct 1999	GB
2403909	Jan 2005	GB
2421190	Jun 2006	GB
2443261	Apr 2008	GB
56-46674	Apr 1981	JP
63309252	Dec 1988	JP
4038960	Feb 1992	JP
8-29699	Feb 1996	JP
2002-369791	Dec 2002	JP
2003-088494	Mar 2003	JP
2003-235852	Aug 2003	JP
2004-33525	Feb 2004	JP
2004-065745	Mar 2004	JP
2005-121947	May 2005	JP
2005-261514	Sep 2005	JP
2006297005	Nov 2006	JP
1021295	Feb 2004	NL
194230	May 1967	SU
980703	Dec 1982	SU
WO 8401707	May 1984	WO
WO 9213494	Aug 1992	WO
WO 9310850	Jun 1993	WO
WO 9320760	Oct 1993	WO
WO 9320765	Oct 1993	WO
WO 9509666	Apr 1995	WO
WO 9622056	Jul 1996	WO
WO 9627331	Sep 1996	WO
WO 9639946	Dec 1996	WO
WO 9712557	Apr 1997	WO
WO 9801080	Jan 1998	WO
WO 9900060	Jan 1999	WO
WO 9909919	Mar 1999	WO
WO 9917661	Apr 1999	WO
WO 9930622	Jun 1999	WO
WO 0035358	Jun 2000	WO
WO 0110319	Feb 2001	WO
WO 0126708	Apr 2001	WO
WO 0141627	Jun 2001	WO
WO 0158360	Aug 2001	WO
WO 0211621	Feb 2002	WO
WO 0234122	May 2002	WO
WO 02094082	Nov 2002	WO
WO 03045260	Jun 2003	WO
WO 03047684	Jun 2003	WO
WO 03059412	Jul 2003	WO
WO 03078721	Sep 2003	WO
WO 03081761	Oct 2003	WO
WO 03082129	Oct 2003	WO
WO 2004006789	Jan 2004	WO
WO 2004028613	Apr 2004	WO
WO 2004037123	May 2004	WO
WO 2004037149	May 2004	WO
WO 2004052221	Jun 2004	WO
WO 2004086984	Oct 2004	WO
WO 2005009211	Feb 2005	WO
WO 2005018467	Mar 2005	WO
WO 2005037088	Apr 2005	WO
WO 2005048827	Jun 2005	WO
WO 2005065284	Jul 2005	WO
WO 2005097019	Oct 2005	WO
WO 2005097234	Oct 2005	WO
WO 2005112810	Dec 2005	WO
WO 2005120363	Dec 2005	WO
WO 2006007399	Jan 2006	WO
WO 2006012630	Feb 2006	WO
WO 2006040109	Apr 2006	WO
WO 2006041881	Apr 2006	WO
WO 2006060405	Jun 2006	WO
WO 2006110733	Oct 2006	WO
WO 2006113216	Oct 2006	WO
WO 2007013059	Feb 2007	WO
WO 2007014063	Feb 2007	WO
WO 2007048085	Apr 2007	WO
WO 2007063550	Jun 2007	WO
WO 2007100067	Sep 2007	WO
WO 2007109171	Sep 2007	WO
WO 2008005433	Jan 2008	WO
WO 2008033356	Mar 2008	WO
WO 2008041225	Apr 2008	WO
WO 2008076337	Jun 2008	WO
WO 2008076800	Jun 2008	WO
WO 2008079440	Jul 2008	WO
WO 2008101075	Aug 2008	WO
WO 2008102154	Aug 2008	WO
WO 2008108863	Sep 2008	WO
WO 2008151237	Dec 2008	WO
WO 2009021030	Feb 2009	WO
WO 2009027065	Mar 2009	WO
WO 2009029065	Mar 2009	WO
WO 2009032623	Mar 2009	WO
WO 2009121017	Oct 2009	WO
WO 2010027688	Mar 2010	WO
WO 2010080974	Jul 2010	WO
WO 2010088481	Aug 2010	WO

Non-Patent Literature Citations (152)

Entry
Written Opinion for PCT/US2009/054453, Mar. 23, 2010 (9 pages).
Zadno et al., “Linear Superelasticity in Cold-Worked NI-TI,” Engineering Aspects of Shape Memory Alloys, pp. 414-419 (1990).
U.S. Appl. No. 13/013,131, filed Jan. 25, 2011.
U.S. Appl. No. 13/013,147, filed Jan. 25, 2011.
U.S. Appl. No. 12/900,132, filed Oct. 7, 2010.
U.S. Appl. No. 12/939,441, filed Nov. 4, 2010.
U.S. Appl. No. 12/902,531, filed Oct. 12, 2010.
U.S. Appl. No. 12/902,550, filed Oct. 12, 2010.
International Search Report for PCT/US2009/054453, Mar. 23, 2010 (8 pages).
Michael S. Kavic, M.D., “Natural Orifice Translumenal Endoscopic Surgery: “NOTES””, JSLS, vol. 10, pp. 133-134 (2006).
Ethicon, Inc., “Wound Closure Manual: Chapter 3 (The Surgical Needle),” 15 pages, (publication date unknown).
Guido M. Sclabas, M.D., et al., “Endoluminal Methods for Gastrotomy Closure in Natural Orifice TransEnteric Surgery (NOTES),” Surgical Innovation, vol. 13, No. 1, pp. 23-30, Mar. 2006.
Fritscher-Ravens, et al., “Transgastric Gastropexy and Hiatal Hernia Repair for GERD Under EUS Control: a Porcine Model,” Gastrointestinal Endoscopy, vol. 59, No. 1, pp. 89-95, 2004.
Ogando, “Prototype Tools That Go With the Flow,” Design News, 2 pages, Jul. 17, 2006.
Edd, et al., “In Vivo Results of a New Focal Tissue Ablation Technique: Irreversible Electroporation,” IEEE Trans Biomed Eng, vol. 53, pp. 1409-1415, 2006.
Kennedy, et al., “High-Burst-Strength, Feedback-Controlled Bipolar Vessel Sealing,” Surgical Endoscopy, vol. 12, pp. 876-878 (1998).
Collins et al., “Local Gene Therapy of Solid Tumors with GM-CSF and B7-1 Eradicates Both Treated and Distal Tumors,” Cancer Gene Therapy, vol. 13, pp. 1061-1071 (2006).
K. Sumiyama et al., “Transesophageal Mediastinoscopy by Submucosal Endoscopy With Mucosal Flap Safety Value Technique,” Gastrointest Endosc., Apr. 2007, vol. 65(4), pp. 679-683 (Abstract).
K. Sumiyama et al., “Submucosal Endoscopy with Mucosal Flap Safety Valve,” Gastrointest Endosc. Apr. 2007, vol. 65(4) pp. 694-695 (Abstract).
K. Sumiyama et al., “Transgastric Cholecystectomy: Transgastric Accessibility to the Gallbladder Improved with the SEMF Method and a Novel Multibending Therapeutic Endoscope,” Gastrointest Endosc., Jun. 2007, vol. 65(7), pp. 1028-1034 (Abstract).
K. Sumiyama et al., “Endoscopic Caps,” Tech. Gastrointest. Endosc., vol. 8, pp. 28-32, 2006.
“Z-Offset Technique Used in the Introduction of Trocar During Laparoscopic Surgery,” M.S. Hershey NOTES Presentation to EES NOTES Development Team, Sep. 27, 2007.
F.N. Denans, Nouveau Procede Pour La Guerison Des Plaies Des Intestines. Extrait Des Seances De La Societe Royale De Medecine De Marseille, Pendant Le Mois De Dec. 1825, et le Premier Tremestre De 1826, Séance Du Feb. 24, 1826. Recueil De La Societe Royale De Medecin De Marseille. Marseille: Impr. D'Achard, 1826; 1:127-31. (with English translation).
I. Fraser, “An Historical Perspective on Mechanical Aids in Intestinal Anastamosis,” Surg. Gynecol. Obstet. (Oct. 1982), vol. 155, pp. 566-574.
M.E. Ryan et al., “Endoscopic Intervention for Biliary Leaks After Laparoscopic Cholecystectomy: A Multicenter Review,” Gastrointest. Endosc., vol. 47(3), 1998, pp. 261-266.
C. Cope, “Creation of Compression Gastroenterostomy by Means of the Oral, Percutaneous, or Surgical Introduction of Magnets: Feasibility Study in Swine,” J. Vasc Interv Radiol, (1995), vol. 6(4), pp. 539-545.
J.W. Hazey et al., “Natural Orifice Transgastric Endoscopic Peritoneoscopy in Humans: Initial Clinical Trial,” Surg Endosc, (Jan. 2008), vol. 22(1), pp. 16-20.
N. Chopita et al., “Endoscopic Gastroenteric Anastamosis Using Magnets,” Endoscopy, (2005), vol. 37(4), pp. 313-317.
C. Cope et al., “Long Term Patency of Experimental Magnetic Compression Gastroenteric Anastomoses Achieved with Covered Stents,” Gastrointest Endosc, (2001), vol. 53, pp. 780-784.
H. Okajima et al., “Magnet Compression Anastamosis for Bile Duct Stenosis After Duct to Duct Biliary Reconstruction in Living Donor Liver Transplantation,” Liver Transplantation (2005), pp. 473-475.
A. Fritscher-Ravens et al., “Transluminal Endosurgery: Single Lumen Access Anastamotic Device for Flexible Endoscopy,” Gastrointestinal Endosc, (2003), vol. 58(4), pp. 585-591.
G.A. Hallenbeck, M.D. et al., “An Instrument for Colorectal Anastomosis Without Sutrues,” Dis Col Rectum, (1963), vol. 5, pp. 98-101.
T. Hardy, Jr., M.D. et al., “A Biofragmentable Ring for Sutureless Bowel Anastomosis. An Experimental Study,” Dis Col Rectum, (1985), vol. 28, pp. 484-490.
P. O'Neill, M.D. et al., “Nonsuture Intestinal Anastomosis,” Am J. Surg, (1962), vol. 104, pp. 761-767.
C.P. Swain, M.D. et al., “Anastomosis at Flexible Endoscopy: An Experimental Study of Compression Button Gastrojejunostomy,” Gastrointest Endosc, (1991), vol. 37, pp. 628-632.
J.B. Murphy, M.D., “Cholecysto-Intestinal, Gastro-Intestinal, Entero-Intestinal Anastomosis, and Approximation Without Sutures (original research),” Med Rec, (Dec. 10, 1892), vol. 42(24), pp. 665-676.
USGI® EndoSurgical Operating System—g-Prox® Tissue Grasper/Approximation Device; [online] URL: http://www.usgimedical.com/eos/components-gprox.htm—accessed May 30, 2008 (2 pages).
Printout of web page—http://www.vacumed.com/zcom/product/Product.do?compid=27&prodid=852, #51XX Low-Cost Permanent Tubes 2MM ID, Smooth Interior Walls, VacuMed, Ventura, California, Accessed Jul. 24, 2007.
Endoscopic Retrograde Cholangiopancreatogram (ERCP); [online] URL: http://www.webmd.com/digestive-disorders/endoscopic-retrograde-cholangiopancreatogram-ercp.htm; last updated: Apr. 30, 2007; accessed: Feb. 21, 2008 (6 pages).
ERCP; Jackson Siegelbaum Gastroenterology; [online] URL: http://www.gicare.com/pated/epdgs20.htm; accessed Feb. 21, 2008 (3 pages).
D.G. Fong et al., “Transcolonic Ventral Wall Hernia Mesh Fixation in a Porcine Model,” Endoscopy 2007; 39: 865-869.
U.S. Appl. No. 11/744,271, filed May 4, 2007.
U.S. Appl. No. 11/744,279, filed May 4, 2007.
U.S. Appl. No. 11/796,035, filed Apr. 26, 2007.
U.S. Appl. No. 11/796,357, filed Apr. 27, 2007.
U.S. Appl. No. 11/894,358, filed Aug. 21, 2007.
U.S. Appl. No. 11/897,676, filed Aug. 31, 2007.
U.S. Appl. No. 11/968,810, filed Jan. 3, 2008.
U.S. Appl. No. 11/981,070, filed Oct. 31, 2007.
U.S. Appl. No. 11/981,078, filed Oct. 31, 2007.
U.S. Appl. No. 11/981,134, filed Oct. 31, 2007.
U.S. Appl. No. 11/986,084, filed Nov. 20, 2007.
U.S. Appl. No. 11/986,420, filed Nov. 21, 2007.
U.S. Appl. No. 11/986,489, filed Nov. 21, 2007.
U.S. Appl. No. 11/998,370, filed Nov. 29, 2007.
U.S. Appl. No. 12/014,417, filed Jan. 5, 2008.
U.S. Appl. No. 12/019,461, filed Jan. 24, 2008.
U.S. Appl. No. 12/045,318, filed Mar. 10, 2008.
U.S. Appl. No. 12/109,673, filed Apr. 25, 2008.
U.S. Appl. No. 12/109,699, filed Apr. 25, 2008.
U.S. Appl. No. 12/115,916, filed May 6, 2008.
U.S. Appl. No. 12/122,031, filed May 16, 2008.
U.S. Appl. No. 12/129,784, filed May 30, 2008.
U.S. Appl. No. 12/129,880, filed May 30, 2008.
U.S. Appl. No. 12/130,010, filed May 30, 2008.
U.S. Appl. No. 12/130,023, filed May 30, 2008.
U.S. Appl. No. 12/130,224, filed May 30, 2008.
U.S. Appl. No. 12/130,652, filed May 30, 2008.
U.S. Appl. No. 12/133,109, filed Jun. 4, 2008.
U.S. Appl. No. 12/133,953, filed Jun. 5, 2008.
U.S. Appl. No. 12/163,255, filed Jun. 27, 2008.
U.S. Appl. No. 12/169,868, filed Jul. 9, 2008.
U.S. Appl. No. 12/170,862, filed Jul. 10, 2008.
U.S. Appl. No. 12/172,752, filed Jul. 14, 2008.
U.S. Appl. No. 12/172,766, filed Jul. 14, 2008.
U.S. Appl. No. 12/172,782, filed Jul. 14, 2008.
U.S. Appl. No. 11/762,855, filed Jun. 14, 2007.
U.S. Appl. No. 12/192,372, filed Aug. 15, 2008.
U.S. Appl. No. 12/203,330, filed Sep. 3, 2008.
U.S. Appl. No. 12/197,653, filed Aug. 25, 2008.
U.S. Appl. No. 12/202,740, filed Sep. 2, 2008.
U.S. Appl. No. 12/203,458, filed Sep. 3, 2008.
U.S. Appl. No. 12/201,812, filed Aug. 29, 2008.
U.S. Appl. No. 12/207,306, filed Sep. 9, 2008.
U.S. Appl. No. 12/243,334, filed Oct. 1, 2008.
U.S. Appl. No. 12/234,425, filed Sep. 19, 2008.
B. Rubinsky, Ph.D., “Irreversible Electroporation in Medicine,” Technology in Cancer Research and Treatment, vol. 6, No. 4, Aug. (2007), pp. 255-259.
How Stuff Works “How Smart Structures Will Work,” http://science.howstuffworks.com/engineering/structural/smart-structure1.htm; accessed online Nov. 1, 2011 (3 pages).
Instant Armor: Science Videos—Science News—ScienCentral; http://www.sciencentral.com/articles./view.php3?article—id=218392121; accessed online Nov. 1, 2011 (2 pages).
Stanway, Smart Fluids: Current and Future Developments. Material Science and Technology, 20, pp. 931-939, 2004; accessed online Nov. 1, 2011 at http://www.dynamics.group.shef.ac.uk/smart/smart.html (7 pages).
Jolly et al., Properties and Applications of Commercial Magnetorheological Fluids. SPIE 5th Annual Int. Symposium on Smart Structures and Materials, 1998 (18 pages).
U.S. Appl. No. 13/036,895, filed Feb. 28, 2011.
U.S. Appl. No. 13/036,908, filed Feb. 28, 2011.
U.S. Appl. No. 13/267,251, filed Oct. 6, 2011.
U.S. Appl. No. 13/325,791, filed Dec. 14, 2011.
U.S. Appl. No. 13/352,495, filed Jan. 18, 2012.
Partial International Search Report for PCT/US2009/054453, Dec. 10, 2009 (2 pages).
D.B. Nelson, MD et al., “Endoscopic Hemostatic Devices,” Gastrointestinal Endoscopy, vol. 54, No. 6, 2001, pp. 833-840.
CRE™ Pulmonary Balloon Dilator; [online] URL: http://www.bostonscientific.com/Device.bsci?page=HCP—Overview&navRe1Id=1000.1003&method=D..., accessed Jul. 18, 2008 (4 pages).
J.D. Paulson, M.D., et al., “Development of Flexible Culdoscopy,” The Journal of the American Association of Gynecologic Laparoscopists, Nov. 1999, vol. 6, No. 4, pp. 487-490.
H. Seifert, et al., “Retroperitoneal Endoscopic Debridement for Infected Peripancreatic Necrosis,” The Lancet, Research Letters, vol. 356, Aug. 19, 2000, pp. 653-655.
K.E. Mönkemüller, M.D., et al., “Transmural Drainage of Pancreatic Fluid Collections Without Electrocautery Using the Seldinger Technique,” Gastrointestinal Endoscopy, vol. 48, No. 2, 1998, pp. 195-200, (Accepted Mar. 31, 1998).
D. Wilhelm et al., “An Innovative, Safe and Sterile Sigmoid Access (ISSA) for NOTES,” Endoscopy 2007, vol. 39, pp. 401-406.
Nakazawa et al., “Radiofrequency Ablation of Hepatocellular Carcinoma: Correlation Between Local Tumor Progression After Ablation and Ablative Margin,” AJR, 188, pp. 480-488 (Feb. 2007).
Miklav{hacek over (c)}i{hacek over (c)} et al., “A validated model of in vivo electric field distribution in tissues for electrochemotherapy and for DNA electrotransfer for gene therapy,” Biochimica et Biophysica Acta, 1523, pp. 73-83 (2000).
Evans, “Ablative and cathether-delivered therapies for colorectal liver metastases (CRLM),” EJSO, 33, pp. S64-S75 (2007).
Wong et al., “Combined Percutaneous Radiofrequency Ablation and Ethanol Injection for Hepatocellular Carcinoma in High-Risk Locations,” AJR, 190, pp. W187-W195 (2008).
Heller et al., “Electrically mediated plasmid DNAa delivery to hepatocellular carcinomas in vivo,” Gene Therapy, 7, pp. 826-829 (2000).
Widera et al., “Increased DNA Vaccine Delivery and Immunogenicity by Electroporation In Vivo,” The Journal of Immunology, 164, pp. 4635-4640 (2000).
Weaver et al., “Theory of electroporation: A review,” Bioelectrochemistry and Bioenergetics, 41, pp. 135-160 (1996).
Mulier et al., “Radiofrequency Ablation Versus Resection for Resectable Colorectal Liver Metastases: Time for a Randomized Trial?” Annals of Surgical Oncology, 15(1), pp. 144-157 (2008).
Link et al., “Regional Chemotherapy of Nonresectable Colorectal Liver Metastases with Mitoxanthrone, 5-Fluorouracil, Folinic Acid, and Mitomycin C May Prolong Survival,” Cancer, 92, pp. 2746-2753 (2001).
Guyton et al., “Membrane Potentials and Action Potentials,” W.B. Sanders, ed. Textbook of Medical Physiology, p. 56 (2000).
Guyton et al., “Contraction of Skeletal Muscle,” Textbook of Medical Physiology, pp. 82-84 (2000).
“Ethicon Endo-Surgery Novel Investigational Notes and SSL Devices Featured in 15 Presentations at Sages,” Apr. 22, 2009 Press Release; URL http://www.jnj.com/connect/news/all/20090422—152000; accessed Aug. 28, 2009 (3 pages).
“Ethicon Endo-Surgery Studies Presented At DDW Demonstrate Potential of Pure NOTES Surgery With Company's Toolbox,” Jun. 3, 2009 Press Release; URL http://www.jnj.com/connect/news/product/20090603—120000; accessed Aug. 28, 2009 (3 pages).
Castellvi et al., “Hybrid Transvaginal NOTES Sleeve Gastrectomy in a Porcine Model Using a Magnetically Anchored Camera and Novel Instrumentation,” Abstract submitted along with Poster at SAGES Annual Meeting in Phoenix, AZ, Apr. 22, 2009 (1 page).
Castellvi et al., “Hybrid Transvaginal NOTES Sleeve Gastrectomy in a Porcine Model Using a Magnetically Anchored Camera and Novel Instrumentation,” Poster submitted along with Abstract at SAGES Annual Meeting in Phoenix, AZ, Apr. 22, 2009 (1 page).
OCTO Port Modular Laparoscopy System for Single Incision Access, Jan. 4, 2010; URL http://www.medgadget.com/archives/2010/01/octo—port—modular—laparo...; accessed Jan. 5, 2010 (4 pages).
Hakko Retractors, obtained Aug. 25, 2009 (5 pages).
U.S. Appl. No. 12/277,975, filed Nov. 25, 2008.
U.S. Appl. No. 12/277,957, filed Nov. 25, 2008.
U.S. Appl. No. 12/332,938, filed Dec. 11, 2008.
U.S. Appl. No. 12/337,340, filed Dec. 17, 2008.
U.S. Appl. No. 12/352,451, filed Jan. 12, 2009.
U.S. Appl. No. 12/359,824, filed Jan. 26, 2009.
U.S. Appl. No. 12/352,375, filed Jan. 12, 2009.
U.S. Appl. No. 12/359,053, filed Jan. 23, 2009.
U.S. Appl. No. 12/362,826, filed Jan. 30, 2009.
U.S. Appl. No. 12/363,137, filed Jan. 30, 2009.
U.S. Appl. No. 12/364,172, filed Feb. 2, 2009.
U.S. Appl. No. 12/364,256, filed Feb. 2, 2009.
U.S. Appl. No. 12/413,479, filed Mar. 27, 2009.
U.S. Appl. No. 12/468,462, filed May 19, 2009.
U.S. Appl. No. 12/607,252, filed Oct. 28, 2009.
U.S. Appl. No. 12/580,400, filed Oct. 16, 2009.
U.S. Appl. No. 12/607,388, filed Oct. 28, 2009.
U.S. Appl. No. 12/612,911, filed Nov. 5, 2009.
U.S. Appl. No. 12/614,143, filed Nov. 6, 2009.
U.S. Appl. No. 12/617,998, filed Nov. 13, 2009.
U.S. Appl. No. 12/640,440, filed Dec. 17, 2009.
U.S. Appl. No. 12/640,469, filed Dec. 17, 2009.
U.S. Appl. No. 12/640,476, filed Dec. 17, 2009.
U.S. Appl. No. 12/640,492, filed Dec. 17, 2009.
U.S. Appl. No. 12/641,823, filed Dec. 18, 2009.
U.S. Appl. No. 12/641,853, filed Dec. 18, 2009.
U.S. Appl. No. 12/641,837, filed Dec. 18, 2009.
U.S. Appl. No. 12/651,181, filed Dec. 31, 2009.
U.S. Appl. No. 12/696,598, filed Jan. 29, 2010.
U.S. Appl. No. 12/696,626, filed Jan. 29, 2010.
U.S. Appl. No. 12/694,452, filed Jan. 27, 2010.
U.S. Appl. No. 12/752,701, filed Apr. 1, 2010.

Related Publications (1)

	Number	Date	Country
	20100049190 A1	Feb 2010	US

Electrical ablation devices

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

CPC

US Classifications

Field of Search

US

International Classifications